Neurobiology of Aging

Epidemiology of Alzheimer's disease
pp. 1-1(1)
Author: Katzman R.

Mild cognitive impairment: Transition from aging to Alzheimer's disease
pp. 1-1(1)
Author: Peterson R.C.

Molecular pathology of prion diseases
pp. 1-1(1)
Authors: Aguzzi A.; Montrasio F.; Brandner S.; Frigg R.; Rockl C.; Fischer M.B.; Pekarik V.; Furukawa H.

Hippocampo-entorhinal complex: Selective vulnerability and neuroplasticity burden
pp. 2-2(1)
Author: Mesulam M.

Hippocampal and entorhinal atrophy in aging Alzheimer's disease: Relation to function
pp. 2-2(1)
Author: Toledo-Morrell L.d.

Functional MRI studies of hippocampal activation in aging and AD
pp. 2-2(1)
Authors: Sperling R.A.; Bates J.C.; Cocchiarella A.J.; Rentz D.M.; Schacter D.L.; Rosen B.R.

Medial temporal lobe atrophy in MCI
pp. 2-2(1)
Author: Jack C.R.

Entorhinal cortex atrophy and apoe
pp. 2-3(2)
Authors: Soininen H.; Laakso M.

Impaired microvascular perfusion in Alzheimer's disease: Role of constitutive nitric oxide
pp. 3-3(1)
Authors: de la Torre J.C.; Stefano G.B.

Clinical and neuropsychological features of aging which predict early Alzheimer's disease
pp. 3-3(1)

Functional imaging in the early detection of cognitive impairment
pp. 3-3(1)
Author: Stern Y.

Neuropsychologoical predictors of cognitive decline
pp. 3-3(1)
Author: Welsh-Bohmer K.A.

A42 and tau as markers in early AD
pp. 4-4(1)
Author: Blennow K.

Biomarkers in predicting early in Alzheimer's disease
pp. 4-4(1)
Author: Galasko D.R.

Long term follow-up of dementia in the community
pp. 4-4(1)
Author: Aguero-Torres H.

Facilitation of -catenin signaling by presenilin-1
pp. 4-4(1)
Author: Koo E.H.

The next step in notch processing and its relevance to APP biology
pp. 4-4(1)
Authors: Kopan R.; Mumm J.S.; Schroeter E.H.; Saxena M.T.; Ray W.J.; Goate A.M.

Association of PSI with GSK-3
pp. 5-5(1)
Authors: Takashima A.; Sun X.; Murayama O.; Murayama M.

Interactions between calsenilin and the presenilins
pp. 5-5(1)
Authors: Wasco W.; Choi E.-K.; Zaidi N.F.; Tekirian T.L.; Buxbaum J.D.

Potential roles of the LDL receptor gene family in Alzheimer disease
pp. 5-5(1)
Author: Herz J.

Pathogenic mechanisms underlying biogenesis of a from amyloid precursor protein
pp. 5-5(1)
Authors: Masters C.L.; Beyreuther K.

Inactive treatment arms in Alzheimer's disease clinical trials
pp. 5-5(1)
Author: Knopman D.S.

Conflicts of interest
pp. 6-6(1)
Author: Clark C.M.

Informed consent
pp. 6-6(1)
Author: Whitehouse P.J.

The research risk assessment
pp. 6-6(1)
Author: Karlawish J.H.

Who is the legal decision-maker with Alzheimer patients?
pp. 6-6(1)
Author: Kapp M.B.

Physical restraints in the care of demented patients
pp. 6-6(1)
Author: Sandman P.-O.

Overview of vascular dementia
pp. 6-6(1)
Author: Markesbery W.R.

Subcortical small vessel dementia
pp. 7-7(1)
Author: Erkinjuntti T.

Lipids, lipoproteins, and the risk of dementia with stroke
pp. 7-7(1)
Author: Moroney J.T.

Neuropathology of cerebrovascular lesions in dementia
pp. 7-7(1)
Author: Brun A.

Cerebrovascular disease and dementia: Clinical pathological correlation
pp. 7-7(1)
Author: Gustafson L.

Vascular smooth muscle cell is the primary target of events leading from notch3 mutations to cadasil
pp. 8-8(1)
Authors: Joutel A.; Francois A.; Gaulis S.; Chapon F.; Godfrain C.; Tournier-Lasserve E.

Update of pharmacologic management of behavioral disturbances in Alzheimer's disease
pp. 8-8(1)
Author: Cummings J.L.

Cholinesterase inhibitors: Benefits and limitations
pp. 8-8(1)
Author: Doody R.S.

Clinical review of non-cholinergic therapies
pp. 8-8(1)
Author: Rockwood K.

Anti-amyloid approaches to treating Alzheimer's disease
pp. 8-8(1)
Author: DeKosky S.T.

Apolipoprotein E, amyloid deposition and Alzheimer's disease: Therapeutic implications
pp. 9-9(1)

Impact of current therapy on Alzheimer's disease progression
pp. 9-9(1)
Author: Giacobini E.

Preventive effect of Japanese green tea against cognitive impairment in the elderly
pp. 9-9(1)

Accelerated amyloid nucleation by oxidatively damaged lipid membranes
pp. 9-9(1)
Authors: Koppaka V.; Weinstein E.; Axelsen P.H.

Effects of amyloid protein on the expressed receptors in xenopus oocytes with MRNA from aged rat brain tissues
pp. 9-9(1)
Authors: Funan H.; Wenbin L.; Binglie Z.; Xu C.; Shuping C.; Hennge X.; Ling Y.; Luning W.

Pharmacological characterization of neuronal glutamate transport in Alzheimer's disease
pp. 10-10(1)
Authors: Scott H.L.; Dodd P.R.

Involvement of presenilins in cell cycle
pp. 10-10(1)
Authors: Jeong S.-J.; Kim H.-S.; Chang K.-A.; Kim K.; Suh Y.-H.

Role of nitric oxide in acute cerebral ischemia and the formation of vascular dementia
pp. 10-10(1)
Authors: Zhang H.; Hu Y.; Tong E.

Metabolically active rat brain slices as a model for studying neurofibrillary degeneration of Alzheimer's disease
pp. 10-10(1)
Authors: Gong C.-X.; Lidsky T.; Wegiel J.; Grundke-Iqbal I.; Iqbal K.

Coherence between regional sources of brain electrical activity in Alzheimer's disease
pp. 10-10(1)
Authors: Jelic V.; Wahlund L.-O.; Huang C.; Julin P.; Winblad B.; Dierks T.

Amyloid AB (1-40) and AB(1-42) adopt remarkably stable, monomeric, and extended structures in water solution at neutral pH
pp. 10-11(2)
Authors: Zagorski M.G.; Shao H.; Ma K.; Yang J.; Li H.; Zeng H.; Zhang Y.; Papolla M.

Detection of intraneouronal oligomers of the amyloid -protein
pp. 11-11(1)

Biophysical and kinetic characterization of amyloid-fibril elongation
pp. 11-11(1)
Authors: Wogulis M.D.; Chilcote T.J.; Fox M.L.; Powell K.A.; Cunningham D.F.; Rydel R.E.

Charge alterations of E22 enhance the pathogenic properties of the amyloid- protein
pp. 11-11(1)
Authors: Melchor J.P.; McVoy L.

Human synuclein exists in both monomeric and polymeric membrane-bound forms in transgenic mice and MES23.5 dopaminergic cells overexpressing WT and A53T mutant synuclein
pp. 11-11(1)
Authors: Sharon R.; Goldberg M.; Selkoe D.J.

Genome-wide linkage disequilibrium mapping of late onset Alzheimer's disease in Finland
pp. 12-12(1)
Authors: Hiltunen M.J.; Mannermaa A.; Pirskanen M.; Koivisto A.; Helisalmi S.; Lehtovirta M.; Ryynanen M.; Soininen H.

Do inhibitors of -amyloid aggregation also inhibit the aggregation of other amyloid-forming peptides?
pp. 12-12(1)
Authors: Moore S.; Davies Y.; Gibson G.; Agnaf O.E.; Allsop D.

C1Q and inflammation in Down syndrome pathogenesis
pp. 12-12(1)
Authors: Head E.; Azizeh B.Y.; Wong S.M.; Lott I.T.; Tenner A.J.; Cotman C.W.; Cribbs D.H.

Tea- and bradykinin(BK)-induced calcium responses in Alzheimer's disease (AD) and control fibroblasts: A ratio index with diagnostic capability
pp. 12-12(1)
Authors: Etcheberrigaray R.; Bhagavan S.; Bank B.; Alkon D.L.

Investigaton of possible associations of 11 poly-morphisms in 8 candidate genes in southeastern African-American Alzheimer disease patients as compared to age-matched controls
pp. 12-13(2)
Authors: Perry R.T.; Collins J.S.; Harrell L.E.; Go R.C.P.

Oligomeric A affects cell function in NGF-differentiated PC12 cells
pp. 13-13(1)
Authors: Rowse L.M.; Desiree Watson M.; Walker G.K.; Emmerling M.R.; LeVine H.X.; Schwarz R.D.

Emotion processing in Alzheimer's disease
pp. 13-13(1)
Authors: Radford S.A.; Bucks R.S.

Communicating about health and memory with dementia and non-dementia patients
pp. 13-13(1)
Author: Sauners P.A.

BRI amyloid precursor protein isoforms. BRI₂ is mutated in familial British dementia
pp. 13-13(1)
Authors: Vidal R.G.; Calero M.; Ghiso J.; Frangione B.

Oligomeric AB in PBS-soluble extracts of human Alzheimer brain
pp. 13-13(1)
Authors: Cherny R.A.; Guerette P.A.; Legg J.T.; Fraser F.W.; Volitakis I.; Masters C.L.

The stick design test: A new measure of visuocon-structural ability in subjects with limited education
pp. 14-14(1)
Authors: Baiyewu O.; Unverzagt F.W.; Gureje O.; Ogunniyi A.O.; Hall K.S.; Hendrie H.C.

Neuroimaging, clinical features and histopathology - A comparison between Lewy body dementia and Alzheimer's disease diagnosed on clinical grounds
pp. 14-14(1)
Authors: Londos E.; Passant U.; Brun A.; Risberg J.; Rosen I.; Gustafson L.

Brush handwriting treatment of cognitive deficiencies in Alzheimer's disease patients
pp. 14-14(1)
Authors: Kao H.S.R.; Gao D.; Wang M.

Selection bias in studies on alpha2-macroglobulin and APOE frequencies and risk estimation
pp. 14-14(1)
Authors: Pirskanen M.; Alafuzoff I.I.; Hiltunen M.J.; Mannermaa A.; Koivisto A.; Helisalmi S.; Lehtovirta M.; Soininen H.

Energy expenditure and Alzheimer disease
pp. 14-15(2)
Authors: Gambina G.; Zamboni M.; Martini M.C.; Broggio E.; Bissoli L.; Mazzali G.; Trevisiol D.; Ferrari G.

Surface APP on platelets from patients with Alzheimer's disease is cleaved in the presence of brain endothelial cells and their medium
pp. 15-15(1)
Authors: Simons E.R.; Eisenhauer P.B.; Dinh K.; Long H.J.; Cribbs D.H.; Davies T.A.

Extrapyramidal signs and the rate of clinical progression in Alzheimer's disease
pp. 15-15(1)
Authors: Pfeffer A.; Golebiowski M.; Czyzewski K.; Wasiak B.; Luczywek E.; Styczynska M.; Barcikowska M.

Effects of FTDP-17 mutations of tau on tau functions
pp. 15-15(1)
Authors: Barghorn S.; von Bergen M.; Ackmann M.; Zheng-Fishhoefer Q.; Wiech H.; Mandelkow E.

Overexpression of tau protein inhibits the outward flow of vesicles and organelles along microtubules
pp. 15-15(1)
Authors: Stamer K.; Trinczek B.; Mandelkow E.-M.

Alfa-D-mannosidases in patients with familial Alzheimer's disease
pp. 16-16(1)
Authors: Orlacchio A.; Tedde A.; Firenze U.; Parnetti L.; Perugia U.; H. St.George-Hyslop P.; Sorbi S.; Emialiani C.

Glycosylation of tau protein occurs earlier than its hyperphosphorylation in Alzheimer's disease
pp. 16-16(1)
Authors: Liu F.; Zaidi T.; Iqbal K.; Grundke-Iqbal I.; Gong C.-X.

Negligible effects of depression on verbal and spatial performance in Alzheimer's disease
pp. 16-16(1)
Authors: Berger A.-K.; Fahlader K.; Wahlin A.; Backman L.

The pathology of REM sleep behavior disorder with lewy body dementia: More than co-incidence
pp. 16-16(1)
Authors: Scott Turner R.; Chervin R.D.

Regional analysis of abnormal tau protein distribution in progressive supranuclear palsy
pp. 17-17(1)
Authors: Zhukareva V.A.; Chin S.S.-M.; Kulstad J.J.; Trojanowski J.Q.; Lee V.M.-Y.

Ibuprofen reduces inflammation and plaque pathology in a mouse model for Alzheimer's disease
pp. 17-17(1)
Authors: Lim G.P.; Yang F.; Chu T.; Chen P.-p.; Beech W.K.; Ubeda O.; Frautschy S.A.

Analysis of the cell distribution of endogenous murine leukemia virus in the brains of SAMRI and SAMP8 mice
pp. 17-17(1)
Authors: Jeong B.-h.; Jin J.-K.; Choi E.-K.; Meeker H.C.; Kozak C.A.; Carp R.I.; Kim Y.-S.

Modification of cysteine proteases and AMPA receptor subunits by the lipid peroxidation product 4-hyroxynonenal: Impact on neuronal apoptosis and necrosis
pp. 17-17(1)
Authors: Chan S.L.; Lu C.; Mattson M.P.

Targeted human apoE replacement mice provide a model for studying the role of apoE in Alzheimer's disease
pp. 18-18(1)
Authors: Sullivan P.M.; Mace B.E.; Schmechel D.E.

Amyloid precursor protein and amyloid--production are altered by caspase inhibition after traumatic brain injury in humanized A mice
pp. 18-18(1)
Authors: Ciallella J.R.; Flood D.G.; Ikonomovic M.D.; Paljug W.; Eduard Dixon C.; Kochanek P.M.; Marion D.W.; DeKosky S.T.

Age-related memory deficits in doubly transgenic mice correlate with amyloid burden
pp. 18-18(1)
Authors: Morgan D.; Gordon M.N.; Diamond D.; King D.; Arendash G.

Inflammatory responses and oxidative stresses in PS/aPP mice
pp. 18-18(1)
Authors: Matsuoka Y.; Picciano M.J.; Malester B.T.; Duff K.

Microglial activation in C57BL/6 and A/J strains of mice leads to different levels of brain inflammation
pp. 18-19(2)
Authors: Dudal S.; Skamene E.; Gervais F.

Cognitive and behavioral improvements in aged primate microcebus murinus following one year treatment with the M1 muscarinic agonist, AF150(S)
pp. 19-19(1)
Authors: Fisher A.; Keller E.

Temporal progression of Alzheimer-like neurode-generation in mice expressing anti-nerve growth factor recombinant antibodies
pp. 19-19(1)
Authors: Capsoni S.; Cattaneo A.

Analysis of high-MR polymers of protein tau in the brain of transgenic mice overexpressing human tau4R
pp. 19-19(1)
Authors: Lasrado R.; Spittaels K.K.; Haute C.V.; Vandenzande K.; Leuven F.V.

Progression of neuropathology in transgenic mice expressing genes linked to familial Alzheimer's disease: APP, PS-1 or both
pp. 19-19(1)
Authors: Moussaoui S.; Tremp G.; Blanchard V.; Bonici B.; Touchet N.; Clavel N.; Pradier L.; Czech C.; Pharma A.

Expression of amyloid precursor protein and presenilin-1 in transgenic mice
pp. 20-20(1)
Authors: Czech C.; Blanchard V.; Clavel N.; Moussaoui S.; Tremp G.; Bonici B.; Touchet N.; Pradier L.; Pharma A.

Aging increases amyloid peptides and causes plaques in brain of old APP/London transgenic mice by a different mechanism than a mutant presenilin-1 transgene
pp. 20-20(1)
Authors: Dewachter I.; Moechars D.; Smeijers L.; Van Dorpe J.; Vanderstichele H.; Checler F.

Staging of neurofibrillary degeneration in a unique cellular model of the role of human tau filament formation in neurofibrillary degenerative disease
pp. 20-20(1)
Authors: Hall G.F.; Reinhold L.; Lee S.; Yao J.

Establishment of the transgenic model of Alzheimers disease
pp. 20-20(1)
Authors: Chuan Q.; Hua Z.; Hongxing Y.; Hong G.; Youyo C.

Sensitive detection of -amyloid aggregation by means of time-resolved fluorescence polarisation anisotropy
pp. 20-21(2)
Authors: Allsop D.; Swanson L.; Moore S.; Davies Y.; El Agnaf O.; Soutar I.

X-34 and other congo red-type amyloid binding agents as in vivo amyloid probes
pp. 21-21(1)
Authors: Klunk W.E.; Wang Y.; Debnath M.L.; Holt D.P.; Mathis C.A.

Microdensitofluorometrically determined free cholesterol is higher in tangle-bearing neurons than in tangle-free neurons
pp. 21-21(1)
Authors: Distl R.; Meske V.

Biochemical diagnosis of Alzheimer's disease
pp. 21-21(1)
Authors: Mulder C.; Scheltens P.; Wahlund L.-O.; Bezemer P.D.; Hack C.E.; Blomberg M.E.; Kamp G.J.

Tramatic brain injury decrease the amount of oligomerized -amyloid peptide in cerebrospinal fluid
pp. 21-21(1)
Authors: Emmerling M.R.; Morganti-Kossmann C.C.; Kossman T.; Stahel P.F.; Watson M.D.; Evans L.M.; Kuo Y.-M.; Roher A.E.

Cerebrospinal fluid tau protein phosphorylated at threonine 231 in Alzheimer's disease patients, healthy controls and subjects at risk
pp. 22-22(1)
Authors: Buerger K.; Kohnken R.E.; Teipel S.J.; Nolde T.; Zinkowski R.; Shen J.; Rapoport S.I.; Hampel H.

Plasma 24S-hydroxycholesterol (cerebrosterol): An indicator of neuronal degeneration and potential state marker for dementia
pp. 22-22(1)
Authors: Papassotiropoulos A.; Lutjohann D.; Bagli M.; Locatelli S.; Jessen F.; Rao M.L.; Maier W.; von Bergmann K.

Mitotic index and Alzheimer's disease
pp. 22-22(1)
Authors: Jenkins E.C.; Ye L.; Gu H.; Li S.-Y.

Withdrawn
pp. 22-22(1)

CSF tau and A correlate with a clinical diagnosis of Alzheimer's disease
pp. 22-22(1)
Authors: Margolin R.A.; McFarland L.

Clinical and neuropsychological correlates of impaired awareness of deficits in Alzheimer's disease (AD) and Parkinson's disease (PD): A comparative study
pp. 23-23(1)
Authors: Seltzer B.; Vasterling J.J.; Mathias C.; Brennan A.

The role of T cell reactivity to A-beta amyloid peptide in the pathogenic processes associated with Alzheimer's disease
pp. 23-23(1)
Authors: Monsonego A.; Maron R.; Bar-Or A.; Krieger J.I.; Selkoe D.; Weiner H.L.

Isolation of CDNA encoding a novel protein that associates with neuron-specific X11L protein
pp. 23-23(1)
Authors: Lee D.-S.; Tomita S.; Takeda S.; Martins R.; Suzuki T.

Phenotypic alterations triggerred by a novel mutation responsible for early onset Alzheimer's disease: A study on APP maturation and apoptotic response
pp. 23-23(1)
Authors: Checler F.; Ancolio K.; Dumanchin C.; Fouques O.; Campion D.; Frebourg T.

Cognitive and behavioral aspects of normal pressure hydrocephalus
pp. 24-24(1)
Authors: Boksay I.; Graves W.W.; Golomb J.; Wisoff J.; Weiner H.

Prediction of treatment response with donepezil in Alzheimer's disease
pp. 24-24(1)
Authors: Chertkow H.M.; Murtha S.J.E.; Bergman H.; Shondorf R.; Phillips N.; Beauregard M.; Chong G.; LeBlanc A.

Cognitive and biological correlates of response to donepezil in Alzheimer's disease
pp. 24-24(1)
Authors: Chertkow H.M.; Murtha S.J.E.; Bergman H.; Shondorf R.; Chong G.; Philips N.; LeBlanc A.

Role of presenilin-1 in neuronal differentiation and migration
pp. 24-24(1)
Authors: Handler M.; Yang X.; Shen J.

Stereologic analysis of vulnerable neocortical neurons in normal aging and Alzheimer's disease
pp. 24-25(2)
Authors: Bussiere T.; Wicinski B.A.; Lin G.I.; Perl D.P.; Davies P.; Nixon R.A.; Morrison J.H.; Hof P.R.

Neuronal apoptosis mediated via proinflammatory secretions from -amyloid stimulated monocytes occurs in a TNF-dependent fashion
pp. 25-25(1)
Authors: Combs C.K.; Karlo J.C.; Kao S.-C.

Variable presentation of Alzheimer's disease and/or spastic paraparesis phenotypes in pedigrees with a novel PS-1 exon 9 gene deletion or exon 9 splice acceptor mutations
pp. 25-25(1)
Authors: Kwok J.B.J.; Smith M.J.; Brooks W.S.; Kril J.; Mclean C.; Hallupp M.; Schofield P.R.

The role of presenilin and the serca-type Ca²⁺-ATPase in notch receptor trafficking and proteolysis
pp. 25-25(1)
Authors: Fortini M.E.; Ye Y.; Periz G.; Lukinova N.I.

Why does dementia need large pragmatic trials?
pp. 25-25(1)
Authors: Qizilbash N.; Schneider L.S.

Progession of patients with mild cognitive decline
pp. 26-26(1)
Authors: Tsolaki M.C.; Kazazi W.; Kazis A.D.

Retrogenesis in Alzheimer's disease: Functional and cognition relationships
pp. 26-26(1)
Authors: Franssen E.H.; Monteiro I.; Boksay I.; Torossian C.; Ferris S.H.; Reisberg B.

Vulnerability to neuroleptic side effects in frontotemporal dementia
pp. 26-26(1)
Authors: Pijnenburg Y.A.L.; Harvey R.J.

Willingness to participate in an Alzheimer's disease prevention trials among mild cognitively impaired elderly
pp. 26-26(1)
Authors: Dominguez-R E.D.; Massoud F.; Sano M.C.

Medication utilization in Alzheimer disease and healthy aging: Results in a research registry
pp. 26-26(1)
Authors: Mizrahi E.H.; Fritsch T.; Geldmacher D.S.; Friedland R.P.; Lerner A.J.

Effects of a rater training program on the clinician interview based impression of change (cibic-plus)
pp. 27-27(1)
Authors: Ferris S.H.; Sinaiko E.A.; Faiz S.; Monteiro I.M.; Reisberg B.; Windscheif U.; Stoeffler A.

Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia
pp. 27-27(1)
Authors: Sahin K.; Stoeffler A.; Furtuna P.; Rosenwald D.; Moebius H.-J.

Investigation of a CA repeat close to the estrogen receptor gene in patients with Alzheimer's disease
pp. 27-27(1)
Authors: Forsell C.; Axelman K.; Blomberg M.E.; Wahlund L.-O.; Enmark E.; Gustafsson J.-O.; Lannfelt L.

Phenomenological dimensions of disinhibition in dementia
pp. 27-27(1)
Authors: Kremer J.L.; Chemerinski E.; Lischinsky A.G.

Impairments of social cognition and decision making in Alzheimer disease
pp. 28-28(1)
Authors: Kremer J.L.; Torralva T.; Dorrego F.; Sabe L.; Chemerinski E.; Fridman E.

Specificity of depressive symptoms in Alzheimer's disease
pp. 28-28(1)
Authors: Starkstein S.E.; Chemerinski E.; Petracca G.

Treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial with a neurotrophic agent
pp. 28-28(1)
Authors: Panisset M.; Gauthier S.; Moessler H.; Windisch M.

The mad-B study: A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzheimer's disease
pp. 28-28(1)
Authors: Ruether E.; Moessler H.; Windisch M.

Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease
pp. 28-29(2)
Authors: Schoenknecht P.; Schroeder J.; Pantel J.; Werle E.; Hartmann T.; Essig M.; Baudendistel K.; Beyreuther K.

Mild cognitive impairment and the neuroanatomical changes associated with assessment of progression to dementia
pp. 29-29(1)
Authors: Murtha S.J.E.; Churchill E.; Chertkow H.M.; Bergman H.; DelCarpio R.

Acupuncture to treat anxiety and depression in Alzheimer's disease and vascular dementia: A pilot feasibility and effectiveness trial
pp. 29-29(1)
Authors: Emerson Lombardo N.B.; Vehvilainen L.; Lock Ooi W.; Volicer L.; McManus C.; Dresser M.; Xu G.; Drebing D.E.

Do vascular alterations play a role in Alzheimers disease?
pp. 29-29(1)
Authors: Marcos A.; Barquero M.-S.; Payno M.; Ramirez C.; Fernandez C.; De Seijas E.V.

Reduction of psychotic symptoms in patients with lewy body-like symptoms treated with olanzapine
pp. 29-29(1)
Authors: Scott Clark W.; Lilly E.; Street J.; Sanger T.; Breier A.

The cerad neuropsychological assessment battery (Cerad-NAB)-A minimal data set as a common tool for German-speaking Europe
pp. 30-30(1)
Authors: Thalmann B.; Urs Monsch A.; Schneitter M.; Bernasconi F.; Aebi C.; Camachova-Davet Z.; Staehelin H.B.

Necker's cube a new tool in dementia evaluation
pp. 30-30(1)
Authors: Fernandez-Viadero C.; Crespo D.; Verduga R.

Which aspect of episodic memory is most vulnerable in a preclinical phase of Alzheimer's disease?
pp. 30-30(1)
Authors: Elfgren C.; Passant U.; Rosen I.; Nilsson L.-G.; Gustafson L.

Demtect: A new screening instrument for supporting diagnosis of dementia
pp. 30-30(1)
Authors: Kessler J.; Calabrese P.; Kalbe E.

Subgroups of Alzheimer disease based on levels of CSF tau, ubiquitin and A_1-42
pp. 31-31(1)
Authors: Khatoon S.; Soininen H.; Lehtovirta M.; Alafuzoff I.I.; Vanmechelen E.J.M.; Grundke-Iqbal I.; Iqbal K.

Psychometric tests and glucose metabolism
pp. 31-31(1)
Authors: Ihl R.; Krause B.; Grass-Kapnake B.; Haupt M.; Mueller-Gaertner H.W.

Investigating statistical models for understanding cognitive decline in the elderly
pp. 31-31(1)
Authors: Lamar M.; Resnick S.M.; Zonderman A.B.

The basel study on the elderly's search for preclinical cognitive markers of Alzheimer's disease
pp. 31-31(1)
Authors: Monsch A.U.; Thalmann B.; Schneitter M.; Bernasconi F.; Aebi C.; Camachova-Davet Z.; Staehelin H.B.

Korean version of the consortium to establish a registry for Alzheimer's disease assessment packet (CERAD-K): Clinical and neuropsychological assessment batteries
pp. 32-32(1)
Authors: Lee J.H.; Lee K.U.; Lee D.Y.; Jhoo J.H.; Kim K.W.; Woo J.I.

The diagnostic evaluation of dementia in general practice in Denmark
pp. 32-32(1)
Author: Waldorff F.B.

Pesticides increase risks of cognitive dysfunction; MAAS prospective cohort study
pp. 32-32(1)
Authors: Bosma H.; Van Boxtel M.P.; Ponds R.W.; Houx P.J.; Jolles J.

Mental work demands protect against cognitive decline; MAAS prospective cohort study
pp. 32-32(1)
Authors: Bosma H.; Van Boxtel M.P.; Ponds R.W.; Houx P.J.; Jolles J.

Apolipoprotein E-4 as a risk factor for Alzheimer and non-Alzheimer'sdementias: Findings from the nun study
pp. 32-33(2)
Authors: Mortimer J.A.; Markesbery W.R.; Snowdon D.A.

Detection of early dementia syndrome of Alzheimer type in epidemiological and clinical samples
pp. 33-33(1)
Authors: Reischies F.M.; Florian W.; Rainer S.T.

Transient ischemic attack predicts time to Alzheimer's disease diagnosis, but other cardiovascular factors do not, the KAME project: A longitudinal study of Japanese Americans in king County, WA
pp. 33-33(1)
Authors: Graves A.B.; McCormick W.C.; Bowen J.D.; McCurry S.M.; Larson E.B.

Risk factors for cognitive decline in healthy older adults
pp. 33-33(1)
Authors: Koss E.; Fritsch T.; Rogus C.J.; Friedland R.P.; Lerner A.J.; Mizrahi E.H.; Siavalas E.L.; Smyth K.A.

Alzheimer's disease in male veterans: Prevalence and risk factors
pp. 33-33(1)
Authors: Hengge X.; Luning W.; Zhenfu W.; Xiaohong W.; Funan H.

APOE genotype, vascular risk and cognitive impairment in an African Caribbean population
pp. 34-34(1)
Authors: Stewart R.; Russ C.; Richards M.; Brayne C.; Lovestone S.; Mann A.

Effects of smoking and alcohol on Alzheimer disease: The mirage study
pp. 34-34(1)
Authors: Cupples A.; Weinberg J.; Beiser A.; Auerbach S.H.; Volicer L.; Growdon J.H.; Wolf P.A.; Farrer L.A.

Lipoprotein(A) affects cognitive function in the elderly. The Italian longitudinal study on aging
pp. 34-34(1)
Authors: Panza F.; Solfrizzi V.; Torres F.; Mastroianni F.; Colacicco A.M.; Capurso C.A.; Scicutella G.; Capurso A.

Decline of language among women and men with Alzheimer's disease
pp. 34-34(1)
Authors: Hebert L.E.; Wilson R.S.; Gilley D.W.; Beckett L.A.; Scherr P.A.; Bennett D.A.; Evans D.A.

Nulliparity and late menopause are associated with less age-related cognitive decline
pp. 34-35(2)
Authors: Lyketsos C.G.; McLay R.

Mortality with dementia: Results from the paquid population-based study
pp. 35-35(1)
Authors: Helmer C.; Joly P.; Letenneur L.; Commenges D.

Apolipoprotein E 4 and stroke are independent risk factors of cognitive decline: Results from a population-based study
pp. 35-35(1)
Authors: Dik M.G.; Deeg D.J.H.; Kok A.; Jonker C.

The relationship between motor performance and cognitive function in older Japanese subjects
pp. 35-35(1)
Authors: Mimori Y.; Yamada M.; Sasaki H.; Kasagi F.; Ikeda J.; Kodama K.; Fujiwara S.

Cognitive functioning and dementia prevalence in older latinos: Cardiovascular and cultural correlates
pp. 35-35(1)
Authors: Haan M.N.; Mungas D.; Gonzalez H.M.; Jagust W.J.

Reduction of the ribosomal RNA in Alzheimer's disease patients
pp. 36-36(1)
Authors: Payao S.M.; Silva A.M.; Borsatto B.; Smith M.A.; Bertolucci P.H.

Tau gene mutations are pleiotropic: Identification of two novel mutations in the tau gene
pp. 36-36(1)
Authors: Stanford P.M.; Halliday G.M.; Brooks W.S.; Kwok J.B.; Storey C.E.; Creasey H.; Morris J.G.; Fulham M.J.

Contribution of APOE as a risk factor for Alzheimer's disease in iceland
pp. 36-36(1)
Authors: Jonsson T.; Magnusdottir E.; Helgadottir H.R.; Petursson H.; Thorisson G.; Jonsson S.; Jonsdottir S.L.; Bjorgvinsdottir I.

Angiotensin converting enzyme insertion/deletion polymorphism and Alzheimer disease risk in African Americans
pp. 36-36(1)
Authors: Evans R.M.; Howard Pratt J.; Murrell J.R.; Ambrosius W.T.; Hall K.S.; Hendrie H.C.

The effect of apolipoprotein E genotypes in Alzheimer's disease: Data from the Canadian study of health and aging
pp. 36-37(2)
Authors: Yee I.M.; Feldman H.; Sadovnick D.

Apolipoprotein E genotype as a predictor of progression from cognitively impaired, but not demented to dementia over a 5-year period
pp. 37-37(1)
Authors: Sadovnick D.; Yee I.M.; Feldman H.

Gender specific association of the angiotensin converting enzyme gene with Alzheimer's disease
pp. 37-37(1)
Authors: Abdullah L.; Crawford F.; Schinka J.; Suo Z.; Gold M.; Duara R.; Mullan M.

Genetics of Alzheimer disease in the Caribbean Hispanic population
pp. 37-37(1)
Authors: Catania J.W.; Santana V.; Estevez P.; Lantigua R.; Medrano M.; Torres Veras M.A.; Zadroga H.R.; Mayeux R.

Withdrawn
pp. 37-37(1)

Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affected IL-6 plasma levels
pp. 38-38(1)
Authors: Licastro F.; Pedrini S.; Bonafe M.; Grimaldi L.M.E.; Olivieri F.; Cavallone L.; Giovannetti S.; Franceschi C.

The association of apolipoprotein E polymorphism and Alzheimer's disease related neuropathological changes is gender- and age-related
pp. 38-38(1)
Authors: Ghebremedhin E.; Schultz C.; Thal D.R.; Rueb U.; Ohm T.; Braak E.; Braak H.

Genetic and clinical follow-up of a twin set discordant for Alzheimer's disease
pp. 38-38(1)
Authors: Bertolucci P.H.; Hideyo Okamoto I.; Marques Payao S.

Lewy bodies may influence symptomatology in some cases of presenilin-related Alzheimer's disease
pp. 38-38(1)
Authors: Lippa C.F.; Nee L.; Pollen D.; Lee V.; Trojanowski J.Q.

Apolipoprotein E allele frequency in African vs African Americans
pp. 38-39(2)
Author: Willis F.B.

A practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease
pp. 39-39(1)
Authors: Matsui T.; Arai H.; Higuchi M.; Okamura N.; Horikawa E.; Sasaki H.

Registration of serial magnetic resonance imaging scans in Alzheimer's disease: Sensitivity and specificity of rates of atrophy
pp. 39-39(1)
Authors: Jenkins R.; Fox N.C.; Rossor M.N.

Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer's disease
pp. 39-39(1)
Authors: van Dyck C.H.; Basso M.; Yang J.; Half L.M.; MacAvoy M.G.; Varma P.; Gelernter J.

Evaluation of cerebral decline in Alzheimer's dementia: Implications for using resting positron emission tomography and magnetic resonance imaging morphometry as outcome measures in long-term treatment studies
pp. 40-40(1)
Authors: Alexander G.E.; Chen K.; Pietrini P.; Rapoport S.I.; Reiman E.M.

A routinely applicable marker based on computed tomography sensitive to Alzheimer's disease and mild cognitive impairment: The radial width of the temporal horn
pp. 40-40(1)
Authors: Frisoni G.B.; Beltramello A.; Pihlajamaki M.; Laakso M.P.; Soininen H.; DeCarli C.; Bianchetti A.; Trabucchi M.

Effect of estrogen on cerebral glucose metabolism in postmenopausal women
pp. 40-40(1)
Authors: Eberling J.L.; Reed B.R.; Coleman J.E.; Jagust W.J.

Longitudinal brain changes in older adults
pp. 40-40(1)
Authors: Resnick S.M.; Davatzikos C.; Kraut M.A.; Zonderman A.B.

Neural representation of nouns in Alzheimer's patients: An fMRI study
pp. 40-41(2)
Authors: Koenig P.; DeVita C.; Alsop D.; Gee J.; Glosser G.; Detre J.; Grossman M.

Proton magnetic resonance spectroscopy of the hippocampus: Normatization in the elderly
pp. 41-41(1)
Authors: Engelhardt E.; Moreira D.M.; Laks J.; Marinho V.M.; Rozenthal M.; Oliveira A.C.

Increased surface expression and processing of amyloid precursor protein in the presence of presenilin 1 mutations
pp. 41-41(1)
Authors: Heyn S.N.; Vulliet R.P.

Regulation of endogenous amyloid -protein production by APOE in a human cortical culture model
pp. 41-41(1)
Authors: Nadeau P.M.; Yuan M.; Geula C.; Weisgraber K.; Younkin S.G.; Yankner B.A.

Oxidative stress induces increase of intracellular a amyloid -protein and selective activation of PKC I and II in NT2 cells
pp. 41-41(1)
Authors: Tabaton M.; Paola D.; Borghi R.; Vitali A.; Zaccheo D.; Marinari U.M.; Odetti P.; Pronzato M.A.

Specific ELISA systems for the detection of endogenous human and rodent ABETA40 and ABETA42
pp. 41-41(1)
Authors: Mercken M.; Brepoels E.; De Jongh M.; Laenen W.; Raeymaekers P.; Geerts H.

The peptidergic antidementia drug cerebrolysin increases neurogenesis in the adult rat dentate gyrus and improves spatial learning and memory
pp. 42-42(1)
Authors: Tatebayashi Y.; Lee M.H.; Iqbal K.; Grundke-Iqbal I.

The role of presenilin 1 in intercellular adhesion
pp. 42-42(1)
Authors: Schwarzman A.L.; Singh N.; Talalayeva Y.; Romanov V.; Dranovsky A.; Shen J.; Yang X.; Goldgaber D.

Molecular mechanism of the neuronal toxicity induced by amyloid--protein(1-40)
pp. 42-42(1)
Authors: Park S.Y.; Rhee S.K.

Homocysteine elicits a DNA damage response in neurons: Mechanism of increased risk for Alzheimer's disease?
pp. 42-42(1)
Authors: Kruman I.I.; Culmsee C.; Chan S.L.; Mattson M.P.

Molecular biological characterization of nicotinic receptors in brain and adrenal medulla
pp. 42-42(1)
Authors: Mousavi M.T.; Nordberg A.; Bednar I.; Linstrom-Lindahl E.

Withdrawn
pp. 43-43(1)

Modulation of APP processing by inhibitors of protein trafficking and cholesterol biosynthesis in mixed cortical cultures from TG+2576 APP mice
pp. 43-43(1)
Authors: Raby C.A.; Emmerling M.R.

Effects of Alzheimer-related presenilin-1 mutations on oxidative stress and cell death in transgenic mice
pp. 43-43(1)
Authors: Eckert A.; Schindowski K.; Leutner S.; Luckhaus C.; Touchet N.; Czech C.; Mueller W.E.

Apoptotic cascades in synaptic terminals: Roles for Par-4, BCL-2 family members and P53 in mitochondrial dysfunction
pp. 43-43(1)
Authors: Duan W.; Chan S.L.; Guo Z.; Mattson M.P.

Caspase-mediated modulation of AMPA receptor function in response to DNA damage in hippocampal neurons: Implications for apoptosis in Alzheimer's disease
pp. 44-44(1)
Authors: Lu C.; Chan S.L.; Mattson M.P.

Dietary restriction and 2-deoxyglucose enhance synaptic glucose and glutamate transport and protect against synaptic dysfunction in experimental models of Alzheimer's disease
pp. 44-44(1)
Authors: Guo Z.; Duan W.; Eroz A.; Batterfield D.A.; Mattson M.P.

The P53 inhibitor pifithrin- protects neurons in experimental models of Alzheimer's disease
pp. 44-44(1)
Authors: Culmsee C.; Zhu X.; Greig N.; Guo Z.; Camandola S.; Crump S.W.; Zhao D.; Mattson M.P.

Modulation of the anti-apoptotic transcription factor NF-B by an endoplasmic reticulum-generated signal
pp. 44-44(1)
Authors: Camandola S.; Glazner G.W.; Mattson M.P.

A neuroprotective role for telomerase in experimental models relevant to the pathogenesis of Alzheimer's disease
pp. 44-45(2)
Authors: Fu W.; Killen M.; Zhu H.; Mattson M.P.

Neuroprotective effect of dietary restriction involves a stress response and increased expression of neurotrophic factors
pp. 45-45(1)
Authors: Lee J.; Duan W.; Herman J.P.; Mattson M.P.

Molecular mechanism of mitochondrial short chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) involved in Alzheimer's disease
pp. 45-45(1)
Authors: He X.-Y.; Merz G.; Yang Y.-Z.; Schulz H.; Yang S.-Y.

Control of transcription of the presenilin 1 gene by ETS transcription factors
pp. 45-45(1)
Authors: Pastorcic M.G.; Das H.K.

BCL-2 protects against apoptosis-related microtubule alterations in neuronal cells: Implications for Alzheimer's disease
pp. 45-45(1)
Authors: Nuydens R.; Dispersyn G.; Van Den Kieboom G.; De Jongh M.; Connors R.; Ramaekers F.; Borgers M.; Geerts H.

Ultra structure evidence of cell death by necrosis in familial Alzheimer's disease (FAD) PS1-E280A brains
pp. 45-45(1)
Authors: Velez-Pardo C.; Tobon-Arroyave S.; Duque-Castano A.; Lopera-Restrepo F.; Jimenez-Del Rio M.

Glutamine synthetase is reduced in astrocytes and abnormally expressed by pyramidal neurons in Alzheimer's disease
pp. 46-46(1)
Author: Robinson S.R.

Cell-free system studies of proteolytic activities generating the Alzheimer's disease A peptide C termini
pp. 46-46(1)
Authors: Bergman A.; Lannfelt L.; Naslund J.

Angiotensin converting enzyme gene polymorphism in presenilin linked Alzheimer's disease families and sporadic acid
pp. 46-46(1)
Authors: Forleo P.; Tedde A.; Nacmias B.; Marcon G.; Orlacchio A.; Sorbi S.

The structure and function of the amyloid precursor protein N-terminal region
pp. 46-46(1)
Authors: Cappai R.; White A.R.; Multhaup G.; Barnham K.; McKinstry W.J.; Needham E.; Galatis D.; Rossjohn J.

Supporting evidence for the existence of a molecular species of presenilin 1 with a seven membrane-spanning and one membrane-embedded structure
pp. 46-47(2)
Authors: Nakai T.; Hagi T.; Miura S.

Dephosphorylation of tau protein induced by neuropsychiatric drugs
pp. 47-47(1)
Authors: Tanaka T.; Tsujio I.; Takeda M.

Withdrawn
pp. 47-47(1)

A role for integrin receptors in attenuating neuronal death
pp. 47-47(1)
Authors: Gary D.S.; Mattson M.P.

The characteristics of anemia associated with vascular dementia in community dwelling elderly Australians
pp. 47-47(1)
Authors: Milward E.A.; Grayson D.A.; Whyte S.; Creasey H.; Janu M.; Anthony Broe G.

Calpain-mediated P35 to P25 conversion is induced by neurotoxic processes and amyloid treatment
pp. 48-48(1)
Authors: Lee M.s.; Kwon Y.; Li M.; Friedlander R.; Tsai L.-H.

Analysis of the functional role of endosomal presenilin-1
pp. 48-48(1)
Authors: Lah J.J.; Levey A.I.

The presenilin gene is very highly conserved throughout evolution
pp. 48-48(1)
Authors: Murray M.M.; Jones C.J.; Clark R.F.

Amyloid fibrils are stochastic assemblies of proteins linked together by a continuous -sheet structure
pp. 48-48(1)
Author: Makowski L.

Analysis of 1184 genes in Alzheimer CA1 hippocampus: Synaptic signaling and transcription factor deficits and upregulation of proinflammatory pathways
pp. 48-49(2)
Authors: Lukiw W.J.; Carver L.A.; LeBlanc H.J.; Bazan N.G.

Studies of the amyloid-APoE interaction reveals a common amyloid recognition site on APOE
pp. 49-49(1)
Authors: Baumann M.H.; Kallijarvi J.

The relationship between ApoE 4 and lipid metabolism is impaired in Alzheimer's disease
pp. 49-49(1)
Authors: Dupuy A.-M.; Mas E.; Cristol J.-P.; Ritchie K.; Touchon J.

Regulation of -amyloid induced cytokine and chemokine expression in rat organotypic hippocampal cultures by macrophage colony stimulating factor
pp. 49-49(1)
Authors: Vincent V.A.M.; Selwood S.P.; Murphy G.M.

Amyloid-beta is a lipoprotein-associated antioxidant which functions by chelating transition metal ions
pp. 49-49(1)
Authors: Kontush A.; Berndt C.; Weber W.; Akopyan V.; Arlt S.

Prion protein abrogates bax-mediated cell death in human primary neuron cultures
pp. 50-50(1)
Authors: Bounhar Y.; Zhang Y.; Papadopoulos M.; Goodyer C.; Hammond J.; LeBlanc A.C.

APP secretion is regulated by activation of PKC and tyrosine kinase in cultured human astrocytes
pp. 50-50(1)
Authors: Kim C.; Bang J.H.; Kim S.U.; Mook-Jung I.

A rapid method to clone large PCR generated APP fragments
pp. 50-50(1)
Authors: Folkesson R.; Winblad B.; Benedikz E.

Effects of copper and zinc on amyloid precursor protein function and metabolism
pp. 50-50(1)
Authors: Multhaup G.; Schlicksupp A.; Schmidt C.; Strauss M.; Borchardt T.; Camakaris J.; Masters C.L.

Regulation of amyloidogenesis and APP trafficking
pp. 50-51(2)
Authors: Murayama O.; Sun X.; Takashima A.

Upregulation of presenilin 1 after A_1-42 injection in a rat retinal model
pp. 51-51(1)
Authors: Bresciani L.G.; Walsh D.T.; Leclercq P.D.; Gentleman S.M.; Jen L.S.

The role of Yen A-synuclein (precursor of the non-amyloid Yen aprotein component of Alzheimer's disease) in various neuronal cells
pp. 51-51(1)
Authors: Seo J.-H.; Min K.; Suh Y.-H.

In vitro analysis of FTDP-17 linked tau mutations
pp. 51-51(1)
Authors: van Slegtenhorst M.; Vink L.; Hutton M.

Characterization of the binding interaction between A and heparin/heparan sulphate
pp. 51-51(1)
Authors: Davidson C.M.; Kisilevsky R.

Monitoring the intracellular fate of apolipoprotein E: Implications for Alzheimer's disease
pp. 51-51(1)
Authors: Ljungberg C.M.; Dayanandan R.; Pearce J.; Anderton B.H.; Lovestone S.

Cellular prion protein mediates laminin-dependent neurite outgrowth in primary cultures of rat and mouse hippocampal neurons
pp. 52-52(1)
Authors: Forlenza O.V.; Zanata S.M.; Graner E.; Mercadante A.F.; Martins V.R.; Prudente F.A.; Brentani R.R.

Characterization of channel formation by Alzheimer's -amyloid protein: Inhibition by estradiol
pp. 52-52(1)
Authors: Kawahara M.; Kuroda Y.

Repression of presenilin 2 expression by oxidative stress
pp. 52-52(1)
Authors: Ghidoni R.; Gasparini L.; Alberici A.; Benussi L.; Finazzi D.; Gatta Luisa B.; Growdon J.H.; Binetti G.G.

Biochemical characterization of -secretase activity that produces -amyloid peptide
pp. 52-52(1)
Authors: Zhang L.; Song L.; Terracina G.; Liu Y.-h.; Pramanik B.; Parker E.M.

Alzheimer's plaques re-created in a test tube: Further insights into the mechanism of amyloid plaque formation
pp. 52-53(2)
Authors: Snow A.D.; Cummings J.A.; Choi P.Y.; Ngo C.; Wight T.N.; Perry G.; DeWitt D.; Castillo G.M.

-Synuclein nitration in neuropathological inclusions
pp. 53-53(1)
Authors: Duda J.E.; Giasson B.I.; Chen Q.; Souza J.M.; Murray I.V.J.; Ischiropoulos H.; Lee V.M.-Y.; Trojanowski J.Q.

Functional role of transcription factors during ainduced neuronal cell death
pp. 53-53(1)
Authors: Bowser R.P.; Jordan-Sciutto K.L.; Rhodes J.L.

Agrin and microvascular damage in Alzheimer's disease
pp. 53-53(1)
Authors: Berzin T.M.; Zipser B.D.; Rafii M.S.; Kuo-Leblanc V.; Yancopoulos G.D.; Glass D.J.; Fallon J.R.; Stopa E.G.

A new subtype of familial early onset Alzheimer's disease with coexisting amyloid and prion pathology
pp. 53-53(1)
Authors: Leuba G.; Saini K.; Savioz A.; Charnay Y.

Topographic distribution of PRP^RES in Creutzfeldt-Jakob disease as revealed by immunohistochemistry
pp. 54-54(1)
Authors: Giaccone G.; Iussich S.; Puoti G.; Rossi G.; Goffredo D.; Tagliavini F.; Bugiani O.

Alteration of vasopressin mRNA expression in the suprachiasmatic nucleus of the patients with Alzheimer disease
pp. 54-54(1)
Authors: Liu R.-Y.; Zhou J.-N.; Hoogendijk W.J.; Van Heerikhuize J.; Kamphorst W.; Unmehopa U.A.; Hofman M.A.; Swaab D.F.

Cortical neurons expressing calcium binding proteins are spared in dementia with Lewy bodies
pp. 54-54(1)
Authors: Estrella G.-T.; Judith S.L.; Kathy N.; Bradley H.T.

The pattern of neurodegeneration in the amygdala in dementia with Lewy bodies differs from that found in Alzheimer's disease
pp. 54-54(1)
Authors: Kowall N.W.; Ferrante R.J.; McKee A.C.

Cerebral hypoperfusion causes boundary zone cortical infarcts in Alzheimer's disease
pp. 54-55(2)
Authors: Suter O.-C.; Kraftsik R.; Darekar P.; Miklossy J.

Enhanced neuronal and astroglial expression of the anti-oxidant enzyme NAD(P)H:Quinone oxido-reductase (NQ01) in the Alzheimer's disease brain
pp. 55-55(1)
Authors: Van Muiswinkel F.L.; Jonkheer S.M.; Rozemuller A.M.; Veerhuis R.; Siegel D.; Sherratt P.J.; O'Connor T.; Drukarch B.

Ubiquitopathies constitute a new class of neuro-degenerative diseases
pp. 55-55(1)
Authors: Sonnemans M.A.; De Vos R.A.; Fischer D.F.; Maat M.; Kamphorst W.; Troost D.; Hol E.M.; Van Leeuwen F.W.

Distribution of neuronal mitogen-activated protein kinase (MAPK) and its upstream MAPK kinase (MAPKK) in human brains staged for Alzheimer's disease neurofibrillary degeneration
pp. 55-55(1)
Authors: Pei J.-J.; Braak E.; Braak H.; Winblad B.; Cowburn R.F.

The recognition of a small group with exclusive mediotemporal pathology (pick D) within the spectrum of frontotemporal dementia
pp. 55-55(1)
Authors: Kamphorst W.; Ravid R.; Swieten J.C.; Heutink P.; Rosso S.M.; Tadema T.; Wouda J.

A starts to deposit on cell surface plasma membrane in diffuse plaques
pp. 56-56(1)
Authors: Yamaguchi H.; Maat-Schieman M.L.C.; van Duinen S.G.; Natte R.; Prins F.A.; Roos R.A.C.

Characterization of amyloid precursor protein carboxy-terminal fragments in Alzheimer disease and Down's syndrome
pp. 56-56(1)
Authors: Russo C.; Gambetti P.L.; Schettini G.

In Down syndrome -amyloid contributes more to neuronal loss than does neurofibrillary degeneration
pp. 56-56(1)
Authors: Tarnawski M.; Wegiel J.; Kuchna I.; Silverman W.; Nowicki K.; Pirttila T.; Krivimaki T.; Lehtimaki T.

The link between accelerated aging and neurofibrillary degeneration in Down syndrome
pp. 56-56(1)
Authors: Kuchna I.; Wegiel J.; Tarnawski M.; Badmaev E.; Pirttila T.; Krivimaki T.; Lehtimaki T.; Morys J.

Neurofibrillary tangles, neuritic plaques, and cerebrovascular lesions at death among demented and cognitively normal Japanese-American men
pp. 57-57(1)
Authors: Petrovitch H.; Steinhorn S.C.; Ross G.W.; Markesbery W.R.; Davis D.G.; Hardman J.; Launer L.J.; White L.R.

-Amyloid peptide does not bind iron after fixation but senile plaques do
pp. 57-57(1)
Authors: Dixon M.M.; Robinson S.R.

Transmission to non-human primates indicates that kuru as well as the ataxic (VV2) or kuruplaque (MV2) variants of sporadic Creutzfeldt-Jakob disease are caused by the same strain of prions
pp. 57-57(1)
Authors: Parchi P.; Brown P.; Capellari S.; Ghetti B.; Gibbs C.J.; Gambetti P.L.

Primary myopathy and accumulation of PRP^SC-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation
pp. 57-57(1)
Authors: Chiesa R.; Pestronk A.; Schmidt R.E.; Pestronk A.; Harris D.A.

Ex vivo propagation of transmissible spongiform encephalopathies agents
pp. 58-58(1)
Authors: Lehmann S.; Nishida N.

A decamer duplication in the BRI gene originates a de-novo amyloid peptide that causes dementia in a Danish kindred
pp. 58-58(1)
Authors: Vidal R.G.; Revesz T.; Rostagno A.; Bek T.; Braendgaard H.; Plant G.; Ghiso J.; Frangione B.

Investigation of the involvement of the prion protein in oxidative stress
pp. 58-58(1)
Authors: Milhavet O.; McMahon H.E.; Nishida N.; Mange A.; Casanova D.; Lehmann S.

Electron microscopy and X-ray diffraction studies further confirm the efficacy of PTI-000703⁽TM) (Cat's claw derivative) as a potent inhibitor of Alzheimer's beta-amyloid protein fibrillogenesis
pp. 58-58(1)
Authors: Castillo G.M.; Kirschner D.A.; Yee A.G.; Snow A.D.

The Arctic APP mutation (E693G) causes Alzheimer's disease through a novel mechanism: Increased amyloid protfibril formation and decreased amyloid levels in plasma and conditioned media
pp. 58-58(1)
Authors: Nilsberth C.; Westlind-Danielsson A.; Eckman C.B.; Forsell C.; Axelman K.; Luthman J.; Younkin S.G.; Nsslund J.

Clinical characteristics in a family with early-onset Alzheimer disease caused by a mutation (V717L) in the APP gene
pp. 59-59(1)
Authors: Hake A.M.; Murrell J.R.; Unverzagt F.W.; Ghetti B.; Farlow M.R.

Aberrant tau splicing caused by mutations associated with inherited dementia
pp. 59-59(1)
Authors: Wu J.; Jiang Z.H.; Cote J.; Kwon J.M.; Goate A.M.; Dupuis S.

Dityrosine cross-linking promotes formation of stable -synuclein polymers
pp. 59-59(1)
Authors: Giasson B.I.; Souza J.M.; Chen Q.; Ischiropoulos H.; Lee V.M.-Y.

Neurofibrillary tangles, neuronal loss, and severe motor changes develop in transgenic mice expressing tau (4R0N) with the frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) mutation P301L
pp. 59-59(1)
Authors: Lewis J.; Davies P.; Yen S.-H.; Dickson D.W.; Hutton M.

Rescue of protein tau-induced axonopathy by GSK-3 in [GSK-3 X HTAU-4R] double transgenic mice
pp. 60-60(1)
Authors: Spittaels K.; Van Den Haute C.; Van Dorpe J.; Geerts H.; Mercken M.; Lasrado R.; Vandezande K.; Van Leuven F.

In vivo analysis of wild-type and FTDP-17 tau mutant mice
pp. 60-60(1)
Authors: Goetz J.M.; Barmettler R.; Probst A.; Goedert M.; Nitsch R.M.

Neuronal expression of human apolipoprotein E4 increases protein tau phosphorylation in transgenic mice
pp. 60-60(1)
Authors: Tesseur I.C.; Van Dorpe J.; Spittaels K.; Van den Haute C.; Bruynseels K.; Van Leuven F.

Improvement of cognitive deficits in female APOE4 transgenic mice after treatment with sex steroids
pp. 60-60(1)
Authors: Raber J.; Su G.; Wong D.; Buttini M.; Mucke L.

Interleukin-1 modulated gene expression in normal human neural progenitor (NHNP) primary cell lines using high density cDNA arrays
pp. 60-61(2)
Authors: Lukiw W.J.; Bazan N.G.

Changes in cognitive characteristics of TG APP CRND8 mice at early stages of immunization with beta amyloid peptide
pp. 61-61(1)
Authors: Janus C.G.; Pearson J.D.; Chishti A.M.; St. George-Hyslop P.; Westaway D.A.

Reduced cerebrospinal fluid estradiol levels are associated with early onset and increased -amyloid levels in Alzheimers disease
pp. 61-61(1)
Authors: Schroeder J.; Pantel J.; Klinga K.; Jensen M.; Schoenknecht P.; Beyreuther K.; Hartmann T.

Neuroendocrine and cognitive response from testosterone treatment in men with Alzheimer's disease
pp. 61-61(1)
Authors: Cherrier M.M.; Asthana S.; Plymate S.; Mohan S.; Baker L.D.; Matsumoto A.; Bremner W.

Enhanced redox interaction of copper-A by homocysteine
pp. 62-62(1)
Authors: Huang X.; Moir R.D.; Atwood C.S.; Goldstein L.E.; Tanzi R.E.; Bush A.I.

Competitive regulation of aredox activity by copper and zinc: Parallels in the pathogenetic mechanisms of Alzheimer's disease and familial amyotrophic lateral sclerosis
pp. 62-62(1)
Authors: Cuajungco M.P.; Atwood C.S.; Huang X.; Lynch T.; Cherny R.A.; Perry G.; Bush A.I.

Hereditary lateral sclerosis and Alzheimer disease associated with mutation at codon 261 of the presenilin 1 (PS1) gene
pp. 62-62(1)
Authors: Farlow M.R.; Murrell J.R.; Hulette C.M.; Ghetti B.

Montessori-based intergenerational programming for dementia: Effects on engagement and affect
pp. 62-62(1)
Authors: Camp C.J.; Spry K.M.

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a one-year, double-blind, randomized trial
pp. 63-63(1)
Authors: Wimo A.; Winblad B.; Mastey V.; Hertzman P.; Haglund A.; Miceli R.; Jacobson L.; Subbiah P.

Effect of apolipoprotein4 and tau gene polymorphisms on age of onset in Swedish Alzheimer's disease sib-pairs
pp. 63-63(1)
Authors: Lilius L.; Axelman K.; Lannfelt L.

Is education protective? Insights from Swedish twin studies
pp. 63-63(1)
Authors: Gatz M.; Svedberg P.; Pedersen N.L.; Mortimer J.A.; Johansson B.; Berg S.

The alpha-2 macroglobulin gene in Alzheimer's disease: A population-based study and meta-analysis
pp. 63-63(1)
Authors: Van Duijn C.M.; Koster M.N.; Dermaut B.; Cruts M.; Houwing-Duistermaat J.J.; Hofman A.; Breteler M.M.B.; Van Broeckhoben C.

Oxidative stress, enzymatic activities and cognitive decline in the EVA study
pp. 64-64(1)
Authors: Berr C.; Richard M.-J.; Gourlet V.; Favier A.

Age specific risk of dementia according to gender, education and wine consumption
pp. 64-64(1)
Authors: Dartigues J.-F.; Letenneur L.; Joly P.; Helmer C.; Orgogozo J.-M.; Commenges D.

Genetic association between Alzheimer's disease and the low density lipoprotein receptor-related protein gene in the French population
pp. 64-64(1)
Authors: Verpillat P.; Bouley S.; Hannequin D.; Belliard S.; Puel M.; Campion D.; Clerget-Darpoux F.; Brice A.

High APOE- allele frequencies in elderly kikuyu in Kenya
pp. 64-64(1)
Authors: Patel N.B.; Kalaria R.N.; Kioy P.; Kariuki M.; Hall K.; Unverzagt F.; Hendrie H.; Friedland R.P.

Lipoprotein(A) is a risk factor for Alzheimer's disease independently of apolipoprotein E genotype
pp. 64-65(2)
Authors: Solfrizzi V.; Panza F.; Torres F.; Mastroianni F.; Colacicco A.M.; Capurso C.A.; Basile A.M.; Capurso A.

Familial frontotemporal dementia with a novel tau exon-10 splice site mutation: Nature confirms a theoretic construct
pp. 65-65(1)
Authors: Dickson D.W.; Le T.V.; Lin W.; Nacharaju P.; Yen S.-H.; Baker M.; Hutton M.L.; Relkin N.

The neuropathology of neurodegeneration with brain iron accumulation, type 1 (NBIA 1) contains insoluble -synuclean
pp. 65-65(1)
Authors: Galvin J.E.; Giasson B.I.; Gambetti P.L.; My Lee V.; Trojanowski J.Q.

Endocytic alterations in human preclinical AD and a trisomic mouse model of down syndrome: Implications for -amyloidogenesis
pp. 65-65(1)
Authors: Cataldo A.M.; Nixon R.A.; Troncoso J.C.; Durham R.A.; Buxbaum J.D.; Epstein C.; Carlson E.; Peterhoff C.M.

Lewy body pathology in familial (presenilin-2) Alzheimer's disease
pp. 66-66(1)
Authors: Fishel M.A.; Tsuang D.W.; Raskind M.A.; Nochlin D.; Schellenberg G.; Bird T.D.; Leverenz J.B.

A S52R mutation in neuroserpin is associated with myoclonic epilepsy and dementia
pp. 66-66(1)
Authors: Yazaki M.; Benson M.D.; Liepnieks J.J.; Farlow M.R.; Piccardo P.; Takao M.; Murrell J.R.; Ghetti B.

Plaque-induced neurite abnormalities in TG2576 HAPPSW over-expressing transgenic mice: Special role of thioflavine S plaques and implications for disruption of the neuropil
pp. 66-66(1)
Authors: Hyman B.T.; Le R.; Cruz L.; Urbanc B.; Augustinack J.; Knowles R.B.; Stanley H.E.

Pathology of flemish APP692 Alzheimer's disease suggests that core containing plaques are angiocenteric
pp. 66-66(1)
Authors: Kumar-Singh S.; Ceuterick C.; Lubke U.; Merken M.; Martin J.-J.; Van Broeckhoven C.

The impact of cerebrovascular disease on Alzheimer pathology in the elderly
pp. 66-67(2)
Authors: Kalaria R.N.; Lewis H.; Cookson N.J.; Shearman M.

Impairment of responses to ER stress in mutant PS1 'knock-in' mouse
pp. 67-67(1)
Authors: Kudo T.; Katayama T.; Imaizumi K.; Nakano Y.; Takeda J.; Tohyama M.; Takeda M.

Absence of presenilin 1 expression enhances -catenin/LEF signaling independently of notch-1
pp. 67-67(1)
Authors: Soriano S.; Kang D.E.; Chevalier N.; Koo E.H.

Presenilns regulators of -secretase cleavage
pp. 67-67(1)
Authors: Golde T.E.; Findlay K.A.; Smith T.E.; Thompson S.; McLendon D.C.; Wang R.; Murphy M.P.

Regulation of notch-1 cleavage and signaling by presenilin-1
pp. 67-67(1)
Authors: Song W.; Nadeau P.M.; Yuan M.; Yang X.; Shen J.; Yankner B.A.

Amino acid 384 of presenilin 1 is part of a putative active domain
pp. 67-67(1)
Authors: Steiner H.; Baader M.; Romig H.; Grim M.G.; Hardy J.A.; Baumeister R.; Haass C.

Presenilin 1 alone is not sufficient to obtain -secretase activity in yeast
pp. 68-68(1)
Authors: Mastrangelo P.; Coomaraswamy J.; Strome R.; Zhang L.; Parker E.M.

PS1 is a regulatory component of the cadherin/catenin adherens junction system
pp. 68-68(1)
Authors: Baki L.; Marambaud P.; Efthimiopoulos S.; Wen P.; Georgakopoulos T.; Robakis N.K.

Effects of staurosporine-mediated cell death on aproduction and caspase-mediated cleavage of amyloid precursor protein and presenilins
pp. 68-68(1)
Authors: Tesco G.; Melikian A.; Kim T.-W.; Kovacs D.M.; Tanzi R.E.

The genetics of Alzheimer's disease
pp. 69-69(1)
Author: Tanzi R.E.

Neuropathology of hereditary tauopathies
pp. 69-69(1)
Author: Ghetti B.

Pathobiology of tauopathies: In vitro and in vivo models
pp. 69-69(1)
Author: Lee V.M.-Y.

Physiological function of APP processing
pp. 69-69(1)
Authors: Beyreuther K.; Masters C.L.

Presenilin-1 is a component of synaptic and endothelial adherens junctions: Implications for FAD
pp. 70-70(1)
Authors: Robakis N.K.; Marambaud P.; Baki L.; Georgakopoulos A.; Shioi J.; Serhan G.; Cui W.; Efthimiopoulos S.

Molecular basis of presenilin's role in APP processing
pp. 70-70(1)
Authors: Selkoe D.J.; Xia W.; Taylor Kimberly W.; Vekrellis K.; Walsh D.; Wolfe M.S.

Intracellular A-beta in neuronal and non-neuronal cells
pp. 70-70(1)
Author: Doms R.W.

Cellular mechanisms of amylod accumulation & pathogenesis
pp. 70-70(1)
Author: Glabe C.G.

Molecular mechanisms of amyloid formation
pp. 70-70(1)
Author: Lansbury P.T.

Neuropsychology of normal aging in the nonhuman primate
pp. 71-71(1)
Author: Rapp P.R.

Estrogen's modulation of brain function in monkeys
pp. 71-71(1)
Author: Voytko M.L.

Age associated memory impairment in rodents
pp. 71-71(1)
Author: Gallagher M.

Mechanism and pathogenesis of cerebral amyloidosis in APP transgenic mice
pp. 71-71(1)
Authors: Jucker M.; Phinney A.; Bondolfi L.; Winkler D.; Tolnay M.; Calhoun M.; Sturchler-Pierrat C.; Staufenbiel M.

Presenilin and ER stress in Alzheimer pathgenesis
pp. 71-71(1)
Authors: Takeda M.; Kudo T.; Imaizumi K.; Tanaka T.; Nakamura Y.; Tohyama M.

Endosomal-lysosomal mechanisms in amyloido-genesis and neurodegeneration: Animal models
pp. 72-72(1)
Authors: Nixon R.A.; Cataldo A.M.; Mathews P.M.; Duff K.; Guerra C.B.; Mohan P.; Jiang Y.; Peterhoff C.

Neuropsychological correlates of early Alzheimer's disease
pp. 72-72(1)
Authors: Ferris S.H.; Kluger A.; Golomb J.; Reisberg B.

Neural circuits compromised in the aged brain
pp. 72-72(1)
Author: Morrison J.H.

Stereological approaches to Alzheimer's disease and age related neuronal loss
pp. 72-72(1)
Authors: West M.J.; Kawas C.; Martin L.J.; Troncoso J.C.

The amyloid paradox resolved - thioflavine positive abeta deposits lead to local neuropil damage and neuronal death
pp. 72-73(2)
Author: Hyman B.T.

Tau protein and Alzheimer's disease: Phosphorylation and role in intracellular trafficking
pp. 73-73(1)
Authors: Mandelkow E.-M.; Ebneth A.; Stamer K.; Aventis R.G.; Drewes G.; Biernat J.; Trinczek B.; Mandelkow E.

Profiles of gene expression in Alzheimer's disease single neurons and tissue homogenates
pp. 73-73(1)
Authors: Coleman P.D.; Callahan L.; Yao P.; Utal A.K.

Early detection of Alzheimer's disease using neuropsychological testing
pp. 73-73(1)
Authors: Albert M.S.; Moss M.B.; Jones K.

Quantitative imaging in preclinical Alzheimer's disease
pp. 73-73(1)
Authors: de Leon M.J.; Convit A.; De Santi S.; Tarshish C.; Wolf O.; Kandil E.; Bobinski M.; Rusinek H.

Increased rates of atrophy in early and preclinical AD: Studies with registration of serial MRI
pp. 74-74(1)
Author: Fox N.C.

Influence of APOE genotype and pet brain imaging on preclinical prediction of Alzheimer disease
pp. 74-74(1)
Authors: Small G.W.; Ercoli L.M.; Silverman D.H.S.; Huang S.C.; Bookheimer S.Y.; Mazziotta J.C.; Barrio J.R.; Phelps M.E.

Brain functional imaging in early and preclinical Alzheimer's disease
pp. 74-74(1)
Author: Nordberg A.

Clinical and pathologic features of early and pre-clinical Alzheimer's disease (AD)
pp. 74-74(1)
Author: Bennett D.A.

Non-pharmacologic approaches to behavior
pp. 74-74(1)
Author: Gwyther L.P.

Integrating pharmacologic and non-pharmacologic treatment into behavioral management
pp. 75-75(1)
Author: Robins P.

Category: (B8) long term management of Alzheimer's disease presentation: Modifying functional decline
pp. 75-75(1)
Author: Beck C.

Which caregiver interventions are of benefit: An evidence based approach
pp. 75-75(1)
Authors: Brodaty H.; Green A.

Alzheimer's disease management from the patients point of view
pp. 75-75(1)
Author: Norberg A.

Functional assessment tools and their use in long term management of Alzheimer's disease
pp. 75-75(1)
Author: Gauthier S.

Genetics and biology of the presenilins and their interacting proteins
pp. 75-75(1)
Authors: St George-Hyslop P.H.; Fraser P.E.; Yu G.; Nishimura M.; Arawaka S.

Cell biology of APP and PS1
pp. 76-76(1)
Author: Thinakaran G.

Role of presenilin 1 and presenilin 2 in APP and Notch processing
pp. 76-76(1)
Authors: De Strooper B.; Annaert W.

Tau pathobiology in transgenic mouse models
pp. 76-76(1)
Authors: Duff K.; Refolo L.M.; Hutton M.; Davies P.

APP and PS-1 transgenic mice
pp. 76-76(1)
Authors: Borchelt D.R.; Lesuisse C.; Gonzales V.; Anderson J.; Lee M.K.; Price D.L.; Wong P.C.Y.; Wagner S.

A as a homeostatic negative regulator of synaptic function?
pp. 76-77(2)
Authors: Kamenetz F.; Borchelt D.R.; Tomita T.; Iwatsubo T.; Sisodia S.; Malinow R.

A de novo designed -helical peptide forms amyloid fibrils which are not neurotoxic
pp. 77-77(1)
Authors: Fezoui Y.; Hartley D.M.; Walsh D.M.; Selkoe D.J.; Osterhut J.J.; Teplow D.B.

An improved method of preparing the amyloid -protein for fibrillogenesis and neurotoxicity experiments
pp. 77-77(1)
Authors: Fezoui Y.; Hartley D.M.; Harper J.D.; Khurana R.; Walsh D.M.; Condron M.M.; Fink A.L.; Teplow D.B.

Denaturation improves the abilities of some globular proteins to inhibit A fibrillogenesis
pp. 77-77(1)
Authors: O'Nuallain B.; Wetzel R.

Cholinesterase inhibitors may exacerbate hypotensive episodes related to neurocardiovascular instability in people with dementia
pp. 77-77(1)
Authors: Kenny R.A.; Ballard C.G.; McLaren A.

Pupil dilation test for Alzheimer's disease
pp. 78-78(1)
Authors: Xiang Z.; Yan W.; Chen Y.

Preventing weight loss in Alzheimer's disease
pp. 78-78(1)
Authors: Vellas B.; Riviere S.; Nourhashemi F.; Gillette-Guyonnet S.; Ousset P.-J.; Micas M.; Lauque S.

P300 in Alzheimer's disease and in primary progressive aphasia: A 3 year follow-up
pp. 78-78(1)
Authors: Paci C.; Thomas A.; D'Andreamatteo G.; Iacono D.; Buongarzone M.P.; Onofrj M.

Association between diffuse amyloid deposits and glial cells in hereditary cerebral hemorrhage with amyloidosis-dutch type
pp. 78-78(1)
Authors: Maat-Schieman M.L.C.; Yamaguchi H.; van Duinen S.G.; Natte R.; Ross R.A.C.

-Secretase inhibitors which have been shown to block A production do not abolish Notch1 signaling
pp. 78-78(1)
Authors: Berezovska O.; Jack C.E.; Aster J.C.; Wolfe M.S.; Selkoe D.J.; Hyman B.T.

Mitochondrial impairment in cerebellum from patients with progressive supranuclear palsy
pp. 79-79(1)
Authors: Park L.C.; Albers D.S.; Beal M.F.; Gibson G.E.

Acupuncture enhancement in clinical symptoms and cognitive-motor abilities of the Alzheimer's disease patients
pp. 79-79(1)
Authors: Kao H.S.R.; Wang M.; Yu S.; Yuan S.; Mao W.; Zhang W.; Wu B.; Gao D.

Clinical features in a kindred with familial frontotemporal dementia with the P301L tau mutation
pp. 79-79(1)
Authors: Boeve B.F.; Hutton M.L.; Lindor N.M.; Ivnik R.J.; Smith G.E.; Jack C.R.; Kokmen E.; Petersen R.C.

Tissue distribution of PRP^SC in variant Creutzfeldt-Jakob disease
pp. 79-79(1)
Authors: Hill A.F.; Joiner S.; Wadsworth J.D.; Collinge J.

IL-1 1S elevated in brain microvessels in Alzheimer's disease
pp. 79-79(1)
Authors: Grammas P.; Ovase R.

Protein aging hypothesis of Alzheimer disease
pp. 80-80(1)
Authors: Orpiszewski J.; Schormann N.; Kluve-Beckerman B.; Liepnieks J.J.; Benson M.D.

Non-pharmacological coordinated treatment for Alzheimer's disease
pp. 80-80(1)
Authors: Zeisel J.R.; Raia P.

Alzheimer's disease in the NAS-NRC Registry of aging veteran twins
pp. 80-80(1)
Authors: Plassman B.L.; Steffens D.C.; Welsh-Bohmer K.A.; Helms M.J.; Newman T.N.; Drosdick D.L.; Meyer J.M.; Breitner J.C.S.

Role of familial British dementia associated BRI/ABRI peptides in glutamatergic synaptic transmission
pp. 80-80(1)
Authors: Parent A.T.; Kim S.H.; Meredith S.C.; Sisodia S.S.

Recent findings in Lewy body dementia
pp. 80-80(1)
Authors: Serby M.; Haroutunian V.; Samuels S.C.; Brickman A.; Purohit D.P.; Davis K.L.

Correlations between hippocampal atrophy and neocortical glucose utilization in Alzheimer's disease: Mapping by SNPM
pp. 81-81(1)
Authors: Meguro K.; Baron J.-C.; Perchey G.; LeMestric C.; Landeau B.; Desgranges B.; Eustache F.; Yamadori A.

Early prediction and longitudinal monitoring of questionably demented, mild Alzheimer's disease and depressed patients as compared to elderly controls: Preliminary results
pp. 81-81(1)
Authors: Swainson R.; Hodges J.R.; Galton C.; Michael A.; Semple J.; Iddon J.L.; Robbins T.W.; Sahakian B.J.

Caspase-3 is activated in Alzheimer disease but not in frontotemporal dementia
pp. 81-81(1)
Authors: Marcon G.; Atzori C.; Srinivasan A.N.; Okazawa H.; Ghetti B.; Migheli A.

Lower activity of Krebs cycle enzymes than of electron transport in human brain: Disease implications
pp. 81-81(1)
Authors: Blass J.P.; Brown A.M.

Apolipoprotein D distribution in normal and Alzheimer's brains: Implications for its role in the pathogenesis of Alzheimer's disease
pp. 82-82(1)
Authors: Ikonomovic M.D.; Desai P.P.; Ilyas Kamboh M.; Hamilton R.; DeKosky S.T.

Overproduction of C9 protein the final component of membrane attack complex in the Alzheimer's brain
pp. 82-82(1)
Authors: Yang L.-B.; Rogers J.B.; Shen Y.

A central executive deficit in short-term maintenance of visuospatial information in early senile dementia of the Alzheimer-type
pp. 82-82(1)
Authors: Dalrymple-Alford J.C.; Mojendie J.E.

Tau association with aggresomes
pp. 82-82(1)
Authors: Nasr P.; Murphy E.K.; Pang Z.; Keller J.N.; Geddes J.W.

Implications of cell surface expression of the Alzheimer's beta-amyloid precursor protein
pp. 82-83(2)
Authors: Jung S.S.; Cashman N.R.

The change of 4.1N message expression in Alzheimer's disease brain
pp. 83-83(1)
Authors: Sharp J.L.; Weimer J.M.; Coleman P.D.

Comparison of the aggregation and fibrillogenesis of ABRI peptides
pp. 83-83(1)
Authors: Gordon D.J.; Miller-Auer H.; Sisodia S.S.; Meredith S.C.

Rapidly progressive aphasic dementia with motor neuron disease: A distinctive clinical entity?
pp. 83-83(1)
Authors: Catani M.; Piccirilli M.; Finali G.; Perticoni G.F.; Alessandro B.; Gianpiero P.; Umberto S.; Patrizia M.

Patients with dementia with Lewy bodies copy the interlocking pentagons on the mini-mental state examination less accurately than patients with Alzheimer disease
pp. 83-83(1)
Authors: Ala T.A.; Hughes L.F.; Kyrouac G.A.; Ghobrial M.W.; Elble R.J.

N-terminal pyroglutamate enhances the fibrillogenic properties of the ABRI peptide in familial British dementia
pp. 84-84(1)
Authors: Miravalle L.; Vidal R.G.; Calero M.; Revesz T.; Plant G.; Frangione B.; Ghiso J.

Acute changes in Alzheimer's disease-related markers after human head trauma
pp. 84-84(1)
Authors: DeKosky S.T.; Ciallella J.R.; Ikonomovic M.D.; Wilbur Y.I.; Paljug W.; Dixon E.E.; Kochanek P.M.; Marion D.W.

Relationship between nitric oxide synthase and choline acetyltransferase in brain in Alzheimer disease
pp. 84-84(1)
Authors: Kalisch B.E.; Baskey J.C.; Davis W.L.; Rylett J.R.

Recognition of non-dementing cognitive impairment of vascular etiology in a memory clinic
pp. 84-84(1)
Authors: Galluzzi S.; Geroldi C.; Bresciani L.C.; Testa C.; Binetti G.G.; Zanetti O.O.; Trabucchi M.; Frisoni G.B.

Generation of adenovirus vectors for cell models of Alzheimer's disease
pp. 84-85(2)
Authors: Vogel R.; Biernat J.; Mandelkow E.

Observations in transgenic mice expressing human wild-type and A30P-mutated -synuclein
pp. 85-85(1)
Authors: Supala A.; Chishti A.M.; Levesque G.; Xu D.H.; Horne P.; Carlson G.A.; Westaway D.; St. George-Hyslop P.H.

Selective deafferentation of the rabbit cortex: A new animal model of Alzheimer's disease
pp. 85-85(1)
Authors: Roher A.E.; Potter P.E.; Kuo Y.-M.; Emmerling M.R.; Durham R.A.; Webster S.D.; Walker D.G.; Beach T.G.

Increased synaptic density in the hippocampus of 24 months old rats after 20 days of treatment with an peptidergic preparation - An explanation for improved spatial memory?
pp. 85-85(1)
Authors: Windisch M.; Reinprecht I.; Windholz E.; Gschanes A.

Alzheimer-like neurodegeneration in aged anti-nerve growth factor transgenic mice
pp. 85-85(1)
Authors: Capsoni S.; Ugolini G.; Comparini A.; Ruberti F.; Berardi N.; Cattaneo A.

Analysis of cerebrospinal fluid beta-amyloid and apolipoprotein E lipoproteins in APP^V717F transgenic mice
pp. 86-86(1)
Authors: DeMattos R.B.; Bales K.R.; Paul S.M.; Holtzman D.M.

Calcium release from internal stores controls the direct association of AKT kinase with presenilin
pp. 86-86(1)
Authors: Haughey N.J.; Gary D.S.; Guo Z.; Mattson M.P.

The development of a human multi-cell culture model of the blood-brain barrier (BBB) for the study of dementia
pp. 86-86(1)
Authors: Brennan S.M.; McGrath L.T.; McIlroy S.P.; Passmore P.A.

Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice
pp. 86-86(1)
Authors: Kim Y.-S.; Kim N.-H.; Jin J.-K.; Kwon M.-S.; Choi E.-K.; Richard R.I.

Evidence for a neuroprotective role for corticotropin-releasing hormone against amyloid toxicity in experimental models of Alzheimer's disease
pp. 86-86(1)
Authors: Pedersen W.A.; McCullers D.; Culmsee C.; Killen M.; Herman J.P.; Mattson M.P.

Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons
pp. 87-87(1)
Authors: Van Dorpe J.A.; Smeijers L.; Dewachter I.; Kurt S.; Van Den Haute C.; Tesseur I.; Sciot R.; Van Leuven F.

Citicoline exerts antiapoptotic effects in an animal model of hippocampal neurodegeneration
pp. 87-87(1)
Authors: Cacabelos R.; Sampedro C.; Alvarez A.

Overexpression of cyclooxygenase-2 MRNA and protein in the brain of scrapie-infected mice
pp. 87-87(1)
Authors: Kim J.-I.; Jin J.-K.; Choi E.-K.; Carp R.I.; Kim Y.-S.

In vivo disrupting of amyloid deposition after injection of -sheet breaker peptide into cerebral ventricle
pp. 87-87(1)
Authors: Permanne B.M.; Saborio G.P.; Soto C.

Influence of double (APP and PS1) mutations on sprouting in the hippocampus following entorhinal cortex lesions in mice and the effects of estrogen
pp. 88-88(1)
Authors: Kadish I.; Van Groen T.

Delayed neurite extension in primary hippocampal cultures from tau knockout mice
pp. 88-88(1)
Authors: Dawson D.N.; Ferreira A.; Eyster M.V.; Scorzafava M.V.; Herbstreith M.V.; Vitek M.P.

The role of alpha-1-antichymotrypsin (ACT) in abeta-amyloidosis of Alzheimer's disease, as studied in novel trigenic PDAPP, mapoe-knockout, GFAP-hACT transgenic mice strains
pp. 88-88(1)
Authors: Nilsson L.N.; DiCarlo G.; Gordon M.N.; Morgan D.G.; Bales K.R.; Paul S.M.; Lilly E.; Potter H.

Accumulation of A in transgenic mice
pp. 88-88(1)
Authors: Prior P.P.; Bayer T.; Lichtenthaler S.F.; Samenfeld P.; Tomic I.; Hartmann T.

A tau PAC transgenic mouse that has developmentally appropriate and tissue specific expression of all six human tau isoforms
pp. 88-89(2)
Authors: Poorkaj P.; Ishihara T.; D'Souza I.; Higuchi M.; Navas P.A.; Lee V.M.Y.; Schellenberg G.D.

Early differential alterations of cholinergic and non-cholinergic cortical presynaptic boutons in transgenic mice displaying amyloid deposition
pp. 89-89(1)
Authors: Hu L.; Wong T.P.; Cote S.L.; Duff K.; Cuello C.A.

In vivo and in vitro experimental axotomy mimics a subtype of dystrophic neurite associated with beta-amyloid plaque formation in Alzheimer's disease
pp. 89-89(1)
Authors: Vickers J.C.; Adlard P.A.; Dickson T.C.; King C.E.

Increased oxidative stress involving olfactory neurons in Alzheimer disease
pp. 89-89(1)
Authors: Perry G.; Smith M.A.; Siedlak S.L.; Tabaton M.; Ghanbari K.; Ghanbari H.

Measurement of A40 and A42 using microdialysis coupled to a sensitive sandwich ELISA
pp. 89-89(1)
Authors: Durham R.A.; Emmerling M.R.; Roher A.E.; Davis M.D.; Walker L.C.

Combination of cerebrospinal fluid tau, A40 and A42 analyses in the diagnosis of Alzheimer's disease
pp. 90-90(1)
Authors: Tapiola T.; Pirttila T.; Mehta P.D.; Alafuzoff I.I.; Lehtovirta M.; Soininen H.

The importance of mitochondrial damage in Alzheimer's disease varies according to APOE genotype
pp. 90-90(1)
Authors: Gibson G.E.; Haroutunian V.; Zhang H.; Park L.C.; Mohs R.C.; Sheu R.K.-F.; Blass J.P.

Amyloid A40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia
pp. 90-90(1)
Authors: Andersen C.; Jensen M.; Lannfelt L.; Lindau M.

Detection of oligomeric -amyloid peptide in biological samples using a singlesite monoclonal antibody sandwich enzyme-linked immunoabsorbant assay
pp. 90-90(1)
Authors: Watson M.D.; Evans L.M.; Haske T.; Spiegel K.; Raby C.A.; Brown K.L.; LeVine H.; Emmerling M.R.

Plasma levels of amyloid proteins in patients with down syndrome do not predict development of dementia
pp. 90-91(2)
Authors: Pirttila T.A.; Tapiola T.; Mehta P.D.; Heikkila L.; Kivimaki T.

Plasma A40 and A42 in Alzheimer's patients during treatment with tacrine
pp. 91-91(1)
Authors: Basun H.; Eckman C.B.; Nilsberth C.; Lannfelt L.; Younkin S.G.

Alzheimer disease and rivastigmine treatment
pp. 91-91(1)
Author: Herrero F.A.

A comparison of co-morbid diseases between African-Americans and white probable Alzheimers disease patients
pp. 91-91(1)
Authors: Harrell L.E.; Zamrini E.Y.; Parson D.S.; Perrish J.; Anderson B.

A twist of the prism: Family & clinician measures of Alzheimer's disease treatment
pp. 91-91(1)
Authors: Graham J.E.; Bassett R.; Stadnyk K.

The relation of migraine, depression and cognition in cadasil
pp. 91-91(1)
Authors: Amberla K.; Waljas M.; Almkvist O.; Poyhonen M.; Tuisku S.; Kalimo H.; Viitanen M.

Insulin and cortisol effects of memory in Alzheimer's disease
pp. 92-92(1)
Authors: Watson G.S.; Baker L.D.; Asthana S.; Peskind E.R.; Craft S.

Accessing health care finance administration beneficiaries as potential participants in a primary prevention trial for Alzheimer's disease
pp. 92-92(1)
Authors: Costa R.; Cross P.; Andrews H.F.; Sano M.C.

Raloxifene: Cognitive-enhancing effects for postmenopausal women with AD
pp. 92-92(1)
Authors: Baker L.D.; Asthana S.; Gleason C.E.; Craft S.; Cholerton B.A.; Watson G.S.; Ahmed S.S.

Neuroendocrine markers of cognition-enhancing efficacy of estrogen in postmenopausal women with Alzheimer's disease
pp. 92-92(1)
Authors: Asthana S.; Baker L.D.; Craft S.; Cholerton B.A.; Gleason C.; Stanzyck F.Z.; Raskind M.A.; Plymate S.R.

Donepezil provides benefits in global function in moderate to severe Alzheimer's disease
pp. 93-93(1)
Authors: Feldman H.; Gauthier S.; Hecker J.; Vellas B.; Subbiah P.; Whalen E.

A model for investigators: Recruiting African-Americans in clinical research
pp. 93-93(1)
Authors: Parfitt F.C.; Epstein D.E.; LaShaune Lawson R.

Development of a scale to predict decline among mildly demented Alzheimer's disease patients
pp. 93-93(1)
Authors: Santillan C.G.; Geldmacher D.S.; Fritsch T.

Effectiveness of donepezil on behavioral disturbances in mild to moderate Alzheimer's disease patients
pp. 93-93(1)
Authors: McRae T.; Griesing T.; Whalen E.

Increasing the relevance of discourse through one-on-one conversation in Alzheimer's disease
pp. 94-94(1)
Authors: Tappen R.M.; Kronk P.B.

334extrapyramidal symptoms and signs in Alzheimer's: Prevalence and correlation with neurological findings
pp. 94-94(1)
Authors: Tsolaki M.; Kokarida K.; Kazis A.D.; Iacovidou V.

Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress
pp. 94-94(1)
Authors: Vellas B.; Feldman H.; Gauthier S.; Hecker J.; Subbiah P.; Whalen E.

Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimer's disease
pp. 94-94(1)
Authors: Panisset M.; Feldman H.; Gauthier S.; Hecker J.; Vellas B.; Subbiah P.; Whalen E.

A brief neuropsychological battery for the early diagnosis of Alzheimer's disease
pp. 95-95(1)
Authors: Abrisqueta-Gomez J.; Bueno O.F.A.; Bertolucci P.H.

Detection of treatment responses in an anti-dementia drug trial using goal attainment scaling
pp. 95-95(1)
Authors: Fay S.; Stadnyk K.; Graham J.E.; Rockwood K.

The cut-off score of a Brazilian geriatric population on neuropsychological task
pp. 95-95(1)
Authors: Silva R.V.; Minett T.S.; Bertolucci P.H.

Donepezil provides long-term clinical benefits for patients with Alzheimer's disease
pp. 95-95(1)
Authors: Pratt R.D.; Gauthier S.; Burns A.; Perdomo C.A.

Correlations between serum cholesterol parameters and plasma amyloid protein
pp. 96-96(1)
Authors: Arvanitakis Z.; Lucas J.A.; Graff-Radford N.R.

A study of diffusion-weighted (DWI) and magnetization transfer imaging (MTI) in patients with Alzheimer's disease (AD)
pp. 96-96(1)
Authors: Franceschi M.; Zuffi M.; Bozzali M.; Cercignani M.; Magnani G.; Comi G.; Filippi M.

Differences in wandering by age, sex, race, and medical basis of dementia
pp. 96-96(1)
Authors: Algase D.L.; Beattie E.R.; Bogue E.-L.

Life satisfaction and depression in long term care staff
pp. 96-96(1)
Author: Austrom M.G.

PC7 contributes to the processing of the Alzheimer's amyloid precursor protein in human cells
pp. 96-97(2)
Authors: Lopez-Perez E.; Seidah N.

The neuropsychological performance of Alzheimer's disease in staging of dementia
pp. 97-97(1)
Authors: Wang Y.; Wang J.

A clinical algorithm for 14-3-3 testing in Creutzfeldt-Jakob disease
pp. 97-97(1)
Authors: Lemstra A.W.; Gool W.A.

Event related evoked potential P300 in frontotemporal dementia
pp. 97-97(1)
Authors: Jimenez-Escrig A.; Fernandez-Lorente J.; Herrero A.; Baron M.; Lousa M.; de Blas G.; Gobernado J.M.

The utility of medial temporal lobe width in discriminating Alzheimer's disease from normal aging
pp. 97-97(1)
Authors: Gao F.-q.; Leibovitch F.S.; Ja Callen D.; Lobaugh N.J.; Black S.E.

CSF tau and beta amyloid may predict conversion from MCI to dementia
pp. 97-97(1)
Authors: Kurz A.F.; Lautenschlager N.T.; Vanmechelen E.; Riemenschneider M.

Development of a culture fair test for anomia in Alzheimer's disease
pp. 98-98(1)
Authors: Tappen R.M.; Kronk P.B.; Touhy T.A.

A successful regional memory screening day for community dwelling elders
pp. 98-98(1)
Authors: Lawrence J.M.; Davidoff D.A.; Auerbach M.; Doss M.; Connell A.J.; Katt-Lloyd D.

Collagen deposition in an experimental model of brain damage and brain sections from patients with Alzheimers disease
pp. 98-98(1)
Authors: Peterson T.C.; Peterson M.R.; Faull R.L.M.; Hong M.G.; Dragunow M.

Indiana Alzheimer disease center national cell repository
pp. 98-98(1)
Authors: Conneally P.M.; Hodes M.E.; Dlouhy S.R.; Fox S.A.

Predicting Alzheimer's disease in subjects with cognitive impairment no dementia using the pre-clinical AD scale (PAS)
pp. 98-99(2)
Authors: Visser P.J.; Verhey F.R.; Jolles J.

Intellectual and physical activities are protective against the development of Alzheimer's disease
pp. 99-99(1)
Authors: Friedland R.P.; Fritsch T.; Smyth K.A.; Koss E.; Lerner A.J.; Chen C.H.; Petot G.J.; Debanne S.M.

A population-based study of family history in relation to dementia and apolipoprotein E polymorphism in 85-year-olds
pp. 99-99(1)
Authors: Tengelin E.G.; Skoog I.G.

The prevalence of dementia in 95-year-olds
pp. 99-99(1)
Authors: Borjesson Hanson A.M.; Gislason T.; Edin E.; Vaghfelt P.; Skoog I.G.

Cognitive function and frontal lobe atrophy is affected by education in normal aging: Implications for dementia as 'age-related' disorders and the reserve hypothesis
pp. 99-99(1)
Authors: Meguro K.; Shimada M.; Yamaguchi S.; Ishizaki J.; Ambo H.; Ishii H.; Shimada Y.; Yamadori A.

APOE 4 is not a significant risk factor for AD in Nigerian Africans
pp. 100-100(1)
Authors: Ogunniyi A.O.; Baiyewu O.; Murrell J.R.; Gureje O.; Lane K.A.; Evans R.M.; Hall K.S.; Hendrie H.C.

Plasma total homocysteine, dementia and mild cognitive impairment
pp. 100-100(1)
Authors: Quadri P.; Fragiacomo C.; Pezzati R.; Capoferri M.; Tettamanti M.; Lucca U.

Gender differences in morbidity, dementia and disability, findings from a population-based study of the oldest old in Stockholm
pp. 100-100(1)
Authors: von Strauss E.I.; Fratiglioni L.; Viitanen M.; Forsell Y.; Winblad B.

The structure of informal care for Alzheimer's disease in Italy
pp. 100-100(1)
Authors: Bianchetti A.; Metitieri T.T.; Vaccaro C.M.; Trabucchi M.

Withdrawn
pp. 100-100(1)

Prevalence of mild cognitive impairment: A population-based study in elderly subjects
pp. 101-101(1)
Authors: Hanninen T.; Hallikainen M.; Vanhanen M.; Soininen H.

The evolution of cognitive impairment in the non-demented elderly. Population data from the Kungsholmen project
pp. 101-101(1)
Authors: Palmer K.M.; Fratiglioni L.; Frisoni G.B.; Viitanen M.

Age at natural menopause and risk of dementia: The Rotterdam study
pp. 101-101(1)
Authors: Geerlings M.I.; Ruitenberg A.; Witteman J.C.M.; Swieten J.C.; Hofman A.; Duijn C.M.; Breteler M.M.B.; Launer L.J.

Risk of nursing home placement and mortality in Alzheimer's disease patients without physical impairment
pp. 101-101(1)
Authors: Khokhar S.R.; Stern Y.; Bell K.L.; Massaoud F.; Albert S.M.

The association between secondary pathology and functional disability in demented subjects
pp. 102-102(1)
Author: Thomas V.S.

Cognitive function in the oldest old: Women perform better than men
pp. 102-102(1)
Authors: van Exel E.; Gussekloo J.; de Craen A.J.; der Wiel A.B.-v.; Houx P.; Knook D.L.; Westendorp R.G.j.

Mild memory impairment and medical care: Results from a population-based study
pp. 102-102(1)
Authors: Albert S.M.; Nadash P.; Stern Y.

The association between dementia and mid-life risk factors
pp. 102-102(1)
Authors: Yamada M.; Mimori Y.; Sasaki H.; Kasagi F.; Musunari N.; Ikeda J.; Nakamura S.; Fujiwara S.

Association studies of novel polymorphisms in BACE and BACE2
pp. 102-103(2)
Authors: Nowotny P.; Chakraverti S.; Kwon J.M.; Goate A.M.

Susceptibility locus for late onset Alzheimer's disease on chromosome 10
pp. 103-103(1)
Authors: Myers A.J.; Goate A.M.; Holmans P.; Williams J.; Owen M.J.; Crook R.; Wavrant-De Vrieze F.; Hardy J.A.

Lack of genetic association of either A2M or LRP with sporadic Alzheimer's disease
pp. 103-103(1)
Authors: McIlroy S.P.; Dynan K.B.; McGleenon B.M.; Vahidassr D.M.; Lawson J.T.; Passmore P.A.

The angiotensin I converting enzyme gene is a susceptibility factor for dementia
pp. 103-103(1)
Authors: Amouyel P.; Richard F.; David-Fromentin I.; Ricolfi F.; Ducimetiere P.; Di Menza C.; Helbecque N.

A genetic linkage study on late-onset familial Alzheimer's disease does not provide strong evidence for linkage to chromosome 1Q22, 9Q21.1, 10Q23, and chromosome 11Q23.3
pp. 103-103(1)
Authors: Rogaeva E.A.; Song Y.Q.; Paterson A.; Richard E.; Nicolaou M.; Sato C.; Liang Y.; Farrer L.A.

No association between 2-macroglobulin DNA polymorphism and Italian sporadic Alzheimer's disease
pp. 104-104(1)
Authors: Nacmias B.; Tedde A.; Cellini E.; Forleo P.; Orlacchio A.; Petruzzi C.; Guarnieri B.M.; Sorbi S.

Ethnicity-dependent association of the cathepsin D C224T polymorphism with Alzheimer's disease
pp. 104-104(1)
Authors: Freeman M.J.; Crawford F.; Duara R.; Gold M.; Michael M.

Linkage disequilibrium as a tool for mapping Alzheimer's disease genes
pp. 104-104(1)
Authors: Perez-Tur J.; Myllykangas L.; Sulkava R.; Verkoniemi A.; Polvikoski T.; Kontula K.; Haltia M.; Hardy J.A.

Estrogen receptor gene polymorphisms in Alzheimer type dementia patients in a Japanese population
pp. 104-104(1)
Authors: Wakutani Y.; Urakami K.; Wada-Isoe K.; Adachi Y.; Yamagata K.; Nakashima K.

An exonic polymorphism of the cathepsin D gene is a major risk factor for Alzheimer's disease
pp. 104-104(1)
Authors: Papassotiropoulos A.; Bagli M.; Kurz A.; Kornhuber J.; Ludwig M.; Maier W.; Heun R.

Association between presenilin-1 mutation Glu318Gly and complaints of memory impairment among non-demented subjects
pp. 105-105(1)
Authors: Laws S.M.; Taddei K.; Clarnette R.M.; Martins G.; Paton A.; Almeida O.P.; Forstl H.; Martins R.N.

Apolipoprotein E genotyping in a sample of Colombian patients with Alzheimer disease
pp. 105-105(1)
Authors: Arboleda G.H.; Arboleda H.; Yunis J.J.; Pardo R.; Gomez C.M.; Hedmont D.; Arango G.

Analysis of mutation of the tau gene in Alzheimer's disease
pp. 105-105(1)
Authors: Urakami K.; Wakutoni Y.; Nakshima K.; Arai H.; Sasaki H.; Higuchi S.; Yamagata K.

Risk factor for Alzheimer's disease: The alpha-2-macroglobuline
pp. 105-105(1)
Authors: Nicosia F.; Benussi L.; Ghidoni R.; Mazzolli F.; Gasparini L.; Frisoni G.B.; Nitsch R.M.; Gb. Binetti G.

Dipeptidyl carboxypeptidase 1 gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with co-existing Alzheimer pathology
pp. 105-105(1)
Authors: Mattila K.M.; Rinne J.O.; Roytta M.; Laippala P.; Kalimo H.; Koivula T.; Frey H.; Lehtimaki T.

Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study
pp. 106-106(1)
Authors: Pihlajamaki M.; Tanila H.; Hanninen T.; Kononen M.; Laakso M.P.; Partanen K.; Soininen H.; Aronen H.J.

Unbiased detection of atrophy in mild to moderate Alzheimer's disease
pp. 106-106(1)
Authors: Rombouts S.A.R.B.; Barhof F.; Witter M.P.; Scheltens P.

Age-transformation of hippocampal volumes improves diagnostic accuracy in Alzheimer's disease
pp. 106-106(1)
Authors: Teipel S.J.; Rapoport S.I.; Bayer W.; Alexander G.E.; Moeller H.-J.

Cognitive deficits and atrophy in specific cortical regions in Alzheimer's disease: A 3D quantitated magnetic resonance study
pp. 106-106(1)
Authors: Acion L.; Capizzano A.A.; Furman M.G.; Bekinschtein T.A.; Gomila H.A.

Reduced cortical thickness of left inferior parietal region in dementia of the Alzheimer's type
pp. 106-107(2)
Authors: Kabani N.J.; Chertkow H.M.; Beauregard M.; Murtha S.J.E.

Withdrawn
pp. 107-107(1)

Functional segregation of medial temporal lobe activation during encoding and recognition of visuospatial scenes
pp. 107-107(1)
Authors: Rombouts S.A.R.B.; Barkhof F.; Witter M.P.; Scheltens P.

Idiopathic selective amnesia with slow onset: A descriptive spect study
pp. 107-107(1)
Authors: Hoegh P.; Sjoe N.; Gade A.; Waldemar G.

Altered brain perfusion in patients with mild to moderate Alzheimer's Disease does not necessarily involve temporarietal neocortex
pp. 108-108(1)
Authors: Paulesu E.; Rocca P.; Zuffi M.; Bottini G.; Basilico S.; Franceschi M.; Fazio F.

Frontal hypometabolism in mild Alzheimer's disease is associated with more rapid progression of dementia
pp. 108-108(1)
Authors: Foster N.L.; Moura V.; Giordani B.; Minoshima S.; Kuhl D.E.

The effect of sodium azide upon the metabolism of amyloid precursor protein
pp. 108-108(1)
Authors: Hedin H.L.M.; Fowler C.J.

Catalase inhibits amyloid -induced cell death in human brain pericytes in vitro
pp. 108-108(1)
Authors: Rensink A.A.M.; Verbeek M.M.; Waalde R.M.W.; Kremer B.

Frameshift mutations in neuronal MRNAS: implications for sporadic Alzheimer's disease
pp. 109-109(1)
Authors: Hol E.M.; Fischer D.F.; Van Leeuwen F.W.

The role of insulin signalling pathway in the regulated secretory processing of the amyloid precursor protein
pp. 109-109(1)
Authors: Racchi M.; Sironi M.; Govoni S.

Involvement of -amyloid precursor protein in the regulation of human neural progenitor cell differentiation
pp. 109-109(1)
Authors: Sugaya K.; Brannen C.L.

Amyloid-peptide insertion is critical for membrane induced fibril assembly: Implication for A-induced neurotoxicity
pp. 109-109(1)
Authors: McLaurin J.; Yip C.M.

Overexpression of tau associates with differentiation of neuronal cells in culture
pp. 110-110(1)
Authors: Haque N.; Zhong J.; Iqbal K.; Grundke-Iqbal I.

Hydroxymethylglutaryl coenzyme a reductase inhibition leads to a caspase-mediated decrease in A secretion by Chinese hamster ovary cells
pp. 110-110(1)
Authors: Haske T.; Evans L.M.; Le Vine H.

Alzheimer's disease presenilin-1 regulates assembly of neurofilaments
pp. 110-110(1)
Authors: Dowjat W.K.; Wisniewski T.

Conformation and toxicity of the ABRI peptide in familial British dementia
pp. 110-110(1)
Authors: Ma El-Agnaf O.; Siligardi G.; Sheridan J.M.; Austen B.M.

The integrity of carboxyl terminus of presenilin 2 is essential for its functions
pp. 110-111(2)
Authors: Tomita T.; Takasugi N.; Takikawa R.; Watabiki T.; Yauchi M.; Iwatsubo T.

CaMKII-dependent phosphorylation of neurofilament-L is induced by visual stimulation of dark-reared rat
pp. 111-111(1)
Authors: Yu N.; Hashimoto R.; Matsumoto N.; Kashiwagi Y.; Fukusho E.; Nakadate K.; Imamura K.; Takeda M.

Involvement of Rho-associated kinase neurite formation of primary neuronal culture
pp. 111-111(1)
Authors: Matsumoto N.; Nakamura Y.; Hashimoto R.; Kashiwagi Y.; Fukusho E.; Takeda M.

Activity of stabilized vegetable extracts against oxidative stress and beta amyloid toxicity
pp. 111-111(1)
Authors: Govoni S.; Masoero E.; Daglia M.; Papetti A.; Racchi M.; Gazzani G.

Interaction of NAC with Aprotein in neuronal cell injury in Alzheimer's disease
pp. 111-111(1)
Authors: Tanaka S.; Takehashi M.; Matoh N.; Masliah E.; Ueda K.

Proinflammatory profile of cytokine expression in APPSW transgenic mice
pp. 112-112(1)
Authors: Tehranian R.; Hasanvan H.; Iverfeldt K.; Post C.; Oostveen J.A.; En Chin J.; Krzesicki R.F.; Schultzberg M.

BACE and BACE2 define a novel subfamily of trans-membrane aspartic proteases
pp. 112-112(1)
Authors: Bennett B.D.; Babu-Khan S.; Loeloff R.; Louis J.-C.; Curran E.; Citron M.; Vassar R.

In-vitro assembly of A 1-40: Morphological investigations and the effect of inhibitors
pp. 112-112(1)

Fibulin-1 binds the amino-terminal head of -amyloid precursor protein and modulates its phyiological function
pp. 112-112(1)
Authors: Ohsawa I.; Takamura C.; Kohsaka S.

Analysis of the role of charge residues in the transmembrane domains of presenilin-2
pp. 112-112(1)
Authors: Reinhard F.B.M.; Eggert S.; Kreger S.; Soba P.A.; Weidemann A.

Neuronal plasticity in Alzheimer's disease
pp. 113-113(1)
Authors: Mikkonen M.; Matto M.; I. Alafuzoff I.; Soininen H.; Miettinen R.

Tau phosphorylation and expression in (non)-neuronal cells expressing wild type of mutant (A692G and E693Q) amyloid precursor protein
pp. 113-113(1)
Authors: Julliams A.; Vanderhoeven I.; Van Broeckhoven C.

Chracterization of inducible transfectants expressing mutated tau identified in FTDP-17
pp. 113-113(1)
Authors: De Ture M.A.; Yen S.-H.; Hutton M.; Easson C.; Ko L.-w.

Slow axonal transport of the microtubule-associated protein tau
pp. 113-113(1)
Authors: Utton M.A.; Killick R.; Grierson A.; Ackerly S.; Lovestone S.; Miller C.

Variable neuron-specific presenilin 1 transcription increases risk for Alzheimer's disease
pp. 113-113(1)
Authors: Theuns J.; Cruts M.; Remacle J.; Corsmith E.; Huylebroeck D.; Van Broeckhoven C.

Neurotrophin receptors in Alzheimer brain and A mouse model of down syndrome
pp. 114-114(1)
Authors: Salehi A.; Cooper J.D.; Alonso M.A.; Swaab D.F.; Mobley W.C.

The female sex hormone estrogen induces an increased release of soluble non-amyloidogenic amyloid precursor protein (SAPP) via the activation of mitogen-activated-protein-kinase (MAPKINASE) and phosphokinase C (PKC)
pp. 114-114(1)
Authors: Manthey D.; Heck S.; Behl C.

Methylation of genes related to Alzheimer disease in neuroblastoma cells
pp. 114-114(1)
Authors: Scarpa S.; Fuso A.; Buttarelli F.; Cavallaro R.; Orru L.; D'Anselmi F.; Giubilei F.

Cytokines stimulate primary human astrocytes to produce amyloid beta
pp. 114-114(1)
Authors: Blasko I.; Stampfer M.; Eikelenboom P.; Grubeck-Loebestein B.

Interaction of apolipoprotein E 4 dosage and activated microglia in deposition of amyloid-40 and amyloid-42 in the elderly
pp. 114-114(1)
Authors: Warzok R.W.; Schroeder E.; Pahnke J.; Pahnke A.; Vogelgesang S.; Walther R.; Stausske D.; Walker L.C.

Apo E and apo E receptor gene expression in the brain of Alzheimer's disease subjects with different apoE genotype
pp. 115-115(1)
Authors: Dea D.; Aumont N.; Poirier J.

Absence of cell surface presenilin 1 in HEK293 and MDCK cells
pp. 115-115(1)
Authors: Tandon A.; Yu H.; Nishimura M.; Yu G.; Fraser P.E.

Quantitative evaluation of -secretase cleavage of amyloid precursor protein in the secretory and endocytic pathways
pp. 115-115(1)
Authors: Steinhilb M.L.; Scott Turner R.; Gaut J.R.

Looking for drug targets for the treatment of neurological disease - a focus on lipid and cholesterol pathways
pp. 115-115(1)
Authors: Schappert K.; Edwards J.; Aumont N.; Lebreton B.; Bywater M.

Insulin degrading enzyme (IDE): implications for the degradation and neurotoxicity of the amyloid -protein
pp. 115-115(1)
Authors: Vekrellis K.; Chesneau V.; Ye Z.; Mansourian S.; Rosner M.; J. Selkoe D.

The Notch transmembrane domain can be cleaved by -secretase
pp. 116-116(1)
Authors: Zhang J.; Ye W.; Greenberg B.D.; Selkoe D.J.

Specific APP -secretase inhibitors do not prevent Notch signalling in vivo
pp. 116-116(1)
Authors: Shearman M.S.; Beck C.; Castro J.L.; Slack J.

Mutated tau locates preferentially to the cytoplasm
pp. 116-116(1)
Authors: Nagiec E.E.; Evans D.B.

Effects on APP processing and A-production by CHAP-21/P519, a second membrane type aspartyl protease related to -secretase
pp. 116-116(1)
Authors: Basi G.S.; Frigon N.; Doan T.; Power M.; Jacobsen-Croak K.; Anderson J.; Knops J.; Soriano F.

Oxidative stress and the calcium stores that are abnormal in fibroblasts from patients with Alzheimer's disease
pp. 116-117(2)
Authors: Zhang H.; Gibson G.E.

The association of PS1 with the neuronal cytoskeleton and its role in Notch signaling and the regulation of neurite outgrowth
pp. 117-117(1)
Authors: Pigino G.; Mori H.; Busciglio J.